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Ewing sarcoma is a devastating pediatric tumor that is particularly aggressive and 
highly metastatic. The current treatment regimen for this malignancy is aggressive, 
invasive and toxic, but with limited success. Treatment of metastatic or relapsed Ewing 
sarcoma is even more dismal with a low 5-year patient survival. My research is focused 
on identifying new mechanisms that could explain early and extensive metastasis in 
Ewing sarcoma potentially enabling better disease outcome in the future. 
In the majority of Ewing sarcoma cases, the causal oncoprotein EWS/FLI 
develops from the reciprocal chromosomal translocation t(11;22)(q24;q12). For this 
dissertation, I analyzed the effect of EWS/FLI oncoprotein on the cellular behavior of 
multiple patient-derived Ewing sarcoma cell lines, and discovered that EWS/FLI 
compromises the cytoskeletal framework of cells. As a result, Ewing sarcoma cells 
display small round cell morphology and low cellular adhesion. I further show that these 
EWS/FLI-dependent changes in cell behavior in vitro are pertinent to tumor cell behavior 
in vivo and could provide relevant insight into the cell of origin for Ewing sarcoma. 
Based on these observations, I suggest a new model where the inciting oncogenic event 
could affect tumor cell adhesion to permit early dissemination of tumor cells or increased 
colonization of tumor cells at a secondary site, to explain early metastasis of tumor cells.  
In this dissertation the analysis of the EWS/FLI transcriptome, revealed that focal 
adhesion proteins, extracellular matrix components, and actin cytoskeletal modulators 




zyxin and the fibronectin receptor α5 integrin were shown to play vital roles in 
modulating Ewing sarcoma cell morphology, cytoskeletal structure, spreading and 
adhesion. 
To adequately study the tumor progression and metastasis of Ewing sarcoma, I 
developed an intratibial orthotopic mouse model. The Ewing sarcoma tumors grew 
aggressively in mice and spontaneously metastasized from the tibia to lungs and other 
bones. This model system recapitulates key features pertinent to the human disease. 
Taken together, the work described in this dissertation reveals the important role 
of EWS/FLI mediated downregulation of adhesion proteins in modulating essential 
cellular features, such as cell adhesion and cytoskeletal structure, to govern oncogenic 
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Metastasis is the primary cause of death in more than 90% of cancer patients 
worldwide (Valastyan and Weinberg, 2011). The term “metastasis,” was coined by the 
French gynecologist Joseph Claude Anthelme Récamier in 1829, to describe the process 
where cancer cells invade the bloodstream of the patient. Now, metastasis is viewed as 
dissemination of cancer cells from the primary cancer site to other organs of the body 
which may be far removed from the primary tumor mass (Talmadge and Fidler, 2010). 
Although many years of research have been dedicated to understanding how cancer cells 
become metastatic, the mechanisms involved in the progression of cancer are still poorly 
understood. Since metastatic disease is associated with poor prognosis, antimetastatic 
drugs might improve patient survival. This ultimately requires a better understanding of 
the process itself to guide the next phase of cancer research. 
Metastasis is considered to be a multistage process with sequential and inter-
related steps. The inability of a cancer cell to complete any of these steps could 
compromise the success of this complex process. A cancer cell poised for metastasis is 
predicted to ensue the following steps: the detachment of tumor cell from the primary 
tumor, its invasion into the surrounding tissue, intravasation (i.e., entry into the blood 
stream), survival in the bloodstream and translocation to distant sites via circulation, 
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extravasation (i.e., exit from the blood stream), reattachment to the new site followed by 
acclimatization to this new tissue microenvironment so that the tumor cell can survive 
and proliferate to form the secondary lesion (Chaffer and Weinberg, 2011). Such a series 
of steps is suggestive of an active process of metastasis that is inefficient and slow. It also 
indicates that metastatic lesions require an established primary tumor to accumulate 
enough mutations over time, making it a later event in cancer progression (Poste and 
Fidler, 1980; Talmadge and Fidler, 2010). This active model of metastasis is based on 
research done on tumors of epithelial origin, especially carcinomas, and often requires an 
epithelial-to-mesenchymal transition (EMT) (Fearon and Vogelstein, 1990; Yang and 
Weinberg, 2008). However, there are certain types of cancer that are metastatic at 
presentation, even when the primary tumor is very small. This multistep model of 
metastasis suggests gradual growth and spread of tumors over a course of time and hence 
does not adequately explain the early stage metastasis seen in several aggressive or 
micrometastatic malignancies.  
No single model can adequately account for occurrence of micrometastatic 
tumors. Several models such as genetic or epigenetic events, effect of environmental 
changes or possible stochastic processes determining tumor cell behavior have been 
suggested but not well characterized. Such tumors may also exhibit early dissemination 
through some yet unknown or not fully understood mechanism to achieve metastasis to 
neighboring and/or distant sites in the body. Especially in tumors of mesenchymal or 
nonepithelial origin, such as sarcomas, the mechanism regulating tumor progression and 
metastasis could be very different from tumors of epithelial origin. In the work described 
in this dissertation, we focused on examining a micrometastatic sarcoma, called Ewing 
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sarcoma, to discover the various factors that could instigate the rapid growth, progression 
and metastasis in nonepithelial tumors.  
This dissertation first reviews the clinical prognosis and the effect of tumor 
microenvironment on the behavior of cancer cells in the primary and secondary sites 
based on current literature (Chapter 2). I then investigate the role that the initiating 
oncogenic event plays to influence the tumor cell phenotype and behavior such as 
appearance of the actin cytoskeleton, cell spreading and cell adhesion (Chapter 3). In 
Chapter 4, I describe how proteins that are present at the interface of the cell membrane 
and the surrounding matrix could be critical in regulating cellular features such as the 
actin cytoskeleton. Based on these findings, I analyzed the downstream targets of the 
oncoprotein that could influence tumor cell spreading, adhesion and actin cytoskeleton in 
vitro and tumor progression and metastasis in vivo in a relevant tissue microenvironment 
(Chapter 5).  Together, by describing oncogene-mediated changes in tumor cell behavior 
and highlighting the contributions of adhesion proteins and interaction of cells with their 
environment, the results from this dissertation are anticipated to advance our knowledge 
of tumor progression and metastasis of nonepithelial tumors in general and Ewing 
sarcoma in particular.  
Ewing sarcoma is a highly metastatic tumor 
 For the purpose of this dissertation, I have studied a highly metastatic non-
epithelial tumor called Ewing sarcoma. Since its first description by James Ewing in 
1921, Ewing sarcoma remains a paradigm for understanding and investigating sarcoma 
biology (Ewing, 1921). Even after decades of research, the prognosis remains extremely 
poor for patients with metastatic or recurrent disease. Although it is a rare pediatric 
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neoplasm, with only 250 new cases identified each year in the United States, it still 
presents a dire future to those affected (Gurney J.G., 1999). While the 5-year survival rate 
for patients with localized disease is 60-70%, it is a dismal 10-30% for patients that 
present with metastatic disease (Figure 1.1) (Kolb et al., 2003; Paulussen et al., 2008). 
Despite the current highly aggressive multimodality treatments that involve surgical 
resection of the tumor, localized radiotherapy and systemic chemotherapy, the cure rates 
have not improved in more than a decade (Dirksen and Jurgens, 2010). These 
disappointing outcomes underscore the need to dissect the molecular mechanisms 
controlling the metastatic or recurrent Ewing sarcoma in order to devise novel treatment 
modalities.  
 In the mid-1980s, the chromosomal translocation t(11;22)(q24;q12) was identified 
to be critical to the pathogenesis, development and maintenance of Ewing sarcoma (Turc-
Carel et al., 1984). This chromosomal rearrangement is present in almost 85% of Ewing 
sarcoma cases and represents the fusion transcript that encodes a portion of EWSR1 
(Ewing’s sarcoma rearrangement domain 1) gene from chromosome 22, and a part of the 
FLI1 (Friend Leukemia virus integration site) gene from chromosome 11 (Turc-Carel et 
al., 1988). The EWSR1 gene encodes the expression of the EWS protein which is a 
member of the TET family of putative RNA-binding proteins and FLI1 is a member of 
the ETS family of transcription factors (Delattre et al., 1992; Morohoshi et al., 1996). The 
fusion of the amino-terminus of EWSR1 with the carboxyl-terminus of FLI1 has several 
important outcomes: (i) the RNA binding portion of EWS is replaced by the DNA 
binding portion of FLI1 protein, (ii) the weak transcriptional activation domain of FLI1 is 
replaced by the strong activation domain of EWSR1, and (iii) the resulting fusion now 
encodes the EWS/FLI protein that is constitutively expressed to function as an aberrant 
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transcription factor and exhibits novel oncogenic properties (Figure 1.2) (Ben-David et 
al., 1990; Lessnick et al., 1995; May et al., 1993b; Potratz et al., 2012).  
 Although EWS/FLI1 is the most common chromosomal translocation associated 
with Ewing sarcoma, other TET/ETS translocations have been observed in about 15% of 
Ewing sarcoma cases (Delattre et al., 1992; Sankar and Lessnick, 2011). These 
observations emphasize the role of chromosomal rearrangements in the pathogenesis of 
Ewing sarcoma. Infact, genetic tests (such as karyotyping) and molecular tests (such as 
RT-PCR analysis) confirming the presence of chromosomal translocation are considered 
strong supportive evidence for diagnosing Ewing sarcoma (Szuhai et al., 2012). In 
addition to these, Ewing sarcoma displays a small, round, undifferentiated blue cell 
phenotype when stained with Hematoxylin and Eosin (Arndt and Crist, 1999) (Figure 
1.3). Furthermore, to distinguish these tumors from other pediatric malignancies, such as 
rhabdomyosarcoma, neuroblastoma and lymphoma, and to positively diagnose the tumors 
as Ewing sarcoma, the presence of cell surface marker CD99 and nuclear FLI1 staining is 
deemed necessary (Folpe et al., 2000; Llombart-Bosch and Navarro, 2001). In this 
dissertation work I have only focused on evaluating the role of EWS/FLI oncoprotein and 
its downregulated targets in influencing Ewing sarcoma biology as shown in Chapters 3 
and 5. 
Role of tumor microenvironment in studying Ewing sarcoma 
Ewing sarcoma is the second most common bone-associated malignancy that 
affects children and young adults and accounts for 34% of all bone malignancies in this 
age group (Gurney J.G., 1999). This osteolytic malignancy typically arises in the 
appendicular and axial or central skeleton. However, in less than 15% of patients it may 
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also arise in the soft tissues and are known as “extra-osseous Ewing sarcoma” (Arndt and 
Crist, 1999; Kimber et al., 1998). Ewing sarcoma has a predilection to involve the shaft 
of long tubular bones, pelvis, and ribs but could arise from any other bone (Kimber et al., 
1998). It is critical to study Ewing sarcoma in the bones due to its distinct tissue 
composition and microenvironment. A brief review of bone biology below will provide a 
good preface for understanding bone (host)-tumor (Ewing sarcoma cell) interaction. 
Structurally, bones can be long or flat, and could be comprised of various 
concentrations of cortical (compact and dense) and trabecular bones (loosely organized 
and porous or “spongy”). Long bones are comprised of epiphysis (ends of bones for 
elongation), diaphysis (long shaft, primarily cortical bone) or metaphysis (largely 
trabecular, interspersed with marrow and blood vessels) (Bussard et al., 2008; Marks, 
2002). Ewing sarcoma primarily develops in the diaphysis or metaphysis of long bones 
(Arndt and Crist, 1999). While radiographic analysis of a bone affected by Ewing 
sarcoma usually reveals an ill-defined, lytic and mottled appearance, the actual extent of 
bone destruction may be greater. It often extends into the soft tissue surrounding the 
tumor, making a clean surgical resection of the tumor very difficult and also affecting 
metastasis. 
There are many features of the bone, which make it a desirable destination for 
cancer cell colonization. As a connective tissue, bone is composed of 95% Type I 
Collagen and the rest 5% is composed of noncollagenous proteins, such as fibronectin in 
its organic matrix (Hancox, 1972). Different kinds of cells reside in the bone, namely 
osteoblasts, osteoclasts, bone marrow stromal cells and hematopoetic cells. It is required 
that cell-cell and cell-matrix interactions among these cells are well coordinated. For 
instance, the osteoblasts release several growth factors, chemokines and cytokines to help 
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with bone growth. Conversely, osteoclasts bind integrins present on the cell surface and 
release lysosomal enzymes to degrade the bone. This synergystic function of these two 
cell types helps the bones to remodel in response to any mechanical strain to maintain 
homeostasis (Bussard et al., 2008; Kanis and McCloskey, 1997). Although these factors 
and enzymes primarily mediate communication between osteoblasts and osteoclasts, they 
can also be used by tumor cells to their advantage. For example, extensive osteolysis in 
Ewing sarcoma could support aggressive tumor growth and metastasis. The factors that 
contribute to the aggressive and highly osteolytic nature of these tumor cells appear to be 
significant to Ewing sarcoma biology and remain to be studied in the bone. An important 
aim of this dissertation has been to study Ewing sarcoma tumor growth in a long bone, 
such as the tibia of male NOD/SCID mice. 
In addition to preferred sites of tumor growth, Ewing sarcoma almost always 
displays tissue-specific metastasis. Despite hematogenous dissemination of Ewing 
sarcoma cells, the tumor cells metastasize to lungs, other bones and bone marrow but not 
other vital organs such as the liver (Arndt and Crist, 1999; Riggi and Stamenkovic, 
2007). This suggests a fundamental role for tissue microenvironment in determining not 
only growth, progression, but also metastasis of Ewing sarcoma.  More than a century 
ago, Stephen Paget proposed the ‘seed and soil’ hypothesis (Paget, 1989) for cancer 
metastasis suggesting that a ‘seed’ (progenitor cells, tumor cells, metastatic cells) could 
colonize and grow in favorable ‘soil’ (microenvironment of tumor cells at the local or 
distant organs, stroma, host factors, tumor cell niche) (Talmadge and Fidler, 2010).  Since 
then, it has been shown that the availability of growth factors and matrices in the tissue 
microenvironment, expression of receptors on the tumor cell surface and the complex 
network of receptor and growth-factor interactions, could affect the malignant behavior 
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of tumors.  The role of tumor microenvironment in the tissue specific dissemination of 
Ewing sarcoma cells is not well characterized. Therefore in this dissertation, we also 
examine the spontaneous sites of metastasis from primary Ewing sarcoma tibial tumors. 
Ewing sarcoma has predilection for bones as the primary site of sarcomagenesis 
and also for metastasis in more than 90% of cases (Guise et al., 2006). Based on the ‘seed 
and soil’ hypothesis, this could be attributed to the abundance of growth factors such as 
basic fibroblast growth factor (b-FGF), platelet derived growth factor (PDGF), 
transforming growth factor β (TGF-β), stem cell factor (SCF, the ligand for c-kit 
receptor), adhesion molecules, cytokines and chemokines present in the bone, providing 
the so-called ‘rich soil’ or ‘favorable environment’ for growth of tumors in the bone 
(Bussard et al., 2008; Mundy, 2002). Some of these factors have been shown to be 
critical to the expression of EWS/FLI or to the tumor growth and metastasis of Ewing 
sarcoma (Girnita et al., 2000).  In addition to this, changes in tumor microenvironment 
such as hypoxic or hypoglycemic conditions also cause phenotypic changes in Ewing 
sarcoma cells (Aryee et al., 2010; Knowles et al., 2010). A better understanding of 
interactions between Ewing sarcoma cells and the surrounding matrix will offer new 
insight towards preventing tumor growth and metastasis of Ewing sarcoma and might 
reveal new therapeutic targets. 
Importance of cellular context to the study of Ewing sarcoma 
In addition to the host environment, it is imperative to study the impact of the 
EWS/FLI oncoprotein in an appropriate cellular context.  The cell of origin for Ewing 
Sarcoma has been the cause of considerable debate since the 1970s. James Ewing first 
described the tumor as a ‘diffused endothelioma of the bone’ (Ewing, 2006). This 
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suggested an endothelial origin for Ewing sarcoma, which was later challenged by 
suggestions of hematological origin, neural crest origin or that of mesenchymal or 
fibroblastic origin in 1980s further perplexing researchers (Cavazzana et al., 1987; 
Dickman et al., 1982; Kadin and Bensch, 1971).  The undifferentiated appearance of 
Ewing sarcoma did not provide much information into the cell of origin; rather the 
presence of mesenchymal markers and several neuroectodermal markers further 
complicated the issue.  
All these studies utilized either microscopic examination or 
immunohistochemistry to correlate the appearance of Ewing sarcoma cells to other cells 
in the cellular milieu present at the anatomic locations from where the tumor cells were 
isolated. However, these studies ignored the possibility that the chromosomal 
translocation t(11;22)(q24;q12) that created EWS/FLI fusion could be responsible for the 
tumor cell phenotype independent of the cell of origin. Gain of function studies by 
putting EWS/FLI in murine and human fibroblasts or by the loss of function studies by 
knocking down EWS/FLI in patient-derived primary Ewing sarcoma cells could be used 
to address this question.  
Through decades of research, scientists in the field have come to realize that the 
biological response to the EWS/FLI oncoprotein expression depends on the cellular 
context (Arvand and Denny, 2001; Kovar, 2005). Several heterologous model systems, 
human and murine alike, have been manipulated to recapitulate Ewing sarcoma, some 
more successful than others. Exogenous expression of EWS/FLI was performed in 
several cell lines, including fibroblast cell lines (human NIH3T3, rodent Rat-1 or mouse 
embryonic), NCM-1 rodent neural crest progenitor cells as well as murine marrow-
derived stromal cells and CTR rhabdomyosarcoma cells (Hu-Lieskovan et al., 2005; May 
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et al., 1993a; Teitell et al., 1999; Toretsky et al., 1997). While NH3T3 cells could be 
transformed to resemble Ewing sarcoma cells, expressing EWS/FLI in other cell lines 
either inhibited cell growth or blocked cellular differentiation as seen in murine marrow-
derived stromal cells (Lessnick et al., 2002; Torchia et al., 2003). Even though NIH3T3 
cells could be transformed by EWS/FLI expression, gene profiling studies revealed that 
these cells do not recapitulate the gene expression pattern of bonafide Ewing sarcoma 
cells derived from patients, thereby limiting the use of this model system to study Ewing 
sarcoma (Braunreiter et al., 2006). 
Based on the most recent body of evidence, mesenchymal stem cells (MSCs) may 
appear to be the true cell of origin for Ewing sarcoma (Riggi et al., 2008; Tirode et al., 
2007). MSCs are an interesting candidate because they are believed to be derived from 
both hematopoetic and neuroectodermal cell lineages (Riggi et al., 2009). When 
EWS/FLI expression was silenced in Ewing sarcoma cell lines, the gene expression 
signature most closely resembled that of MSC (Tirode et al., 2007). Conversely, when 
EWS/FLI was expressed in MSCs, the gene expression signature was very similar to that 
of patient-derived Ewing sarcoma cells, but the MSCs did not form tumors in immuno-
compromised mice (Riggi et al., 2008). This finding further suggests that EWS/FLI 
expression is not sufficient to transform MSCs into Ewing sarcoma cells, and perhaps 
additional or cooperative mutations or a more permissive microenvironment are required 
for complete transformation. Alternatively, it should be noted that MSCs are not 
confirmed cell of origin for Ewing sarcoma and based on above experimental 
consequences it is possible that may be MSCs are not the cell of origin for Ewing 
sarcoma. 
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 Controversies surrounding the cell of origin for Ewing sarcoma, prompted us to 
choose a loss of function approach in patient-derived Ewing sarcoma cells. The 
retrovirally mediated shRNA-based knockdown of endogenous EWS/FLI expression in 
patient-derived cell lines (such as A673, EWS502, TC71) facilitated the work described 
in this dissertation.  Using this unique knockdown approach, the cells lost EWS/FLI-
mediated oncogenic transformation in vitro and tumor formation in vivo (Smith et al., 
2006). The microarray analysis performed to verify the transcriptional profile of 
EWS/FLI using this technique identified a core set of genes that are known dysregulated 
targets of EWS/FLI, thereby validating the use of this approach to study EWS/FLI 
mediated effects on cell behavior in Chapters 3 and 5 (Kinsey et al., 2006; Luo et al., 
2009; Smith et al., 2006; Tirado et al., 2006). 
EWS/FLI-driven changes in cell behavior are essential  
to Ewing sarcoma biology 
It needs to be explored how EWS/FLI makes changes in cellular behavior to drive 
Ewing sarcoma metastasis, in addition to inciting oncogenic transformation. It can be 
assumed that, being an aberrant transcriptional factor, EWS/FLI oncoprotein affects the 
gene expression patterns in Ewing sarcoma cells to modulate tumor cell phenotype. We 
used the aforementioned EWS/FLI knockdown approach to examine the role of this 
oncoprotein to influence changes in cell morphology, adhesion, spreading, migration and 
invasion. For the progression and metastasis of tumors of epithelial origin, the role of 
surrounding tissue microenvironment in influencing tumor cell behavior have been 
deemed vital and are extensively studied (Thiery and Sleeman, 2006; Yilmaz and 
Christofori, 2009). It is important to explore if the matrix composition of the tissue at the 
primary and the secondary site are also relevant in sarcomas and other nonepithelial 
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cancers. This dissertation not only investigates whether EWS/FLI affects these vital 
cellular features and processes but also how the interaction of tumor cell with its 
surrounding tissue matrix influences Ewing sarcoma tumor progression and metastasis.  
Extracellular matrix, integrins and focal adhesions 
influence cell behavior 
As a tumor grows and metastasizes, the tumor cells experience several intrinsic 
(genetic/epigenetic modifications) or extrinsic (cues from surrounding matrix, growth 
factors, chemotactic and mechanical stimuli) pressures, to which they must survive, adapt 
and, proliferate (Hynes, 1992; Ingber et al., 1981; Lelievre et al., 1998; Yilmaz and 
Christofori, 2009). Cells must adhere to the surrounding extracellular matrix (ECM) for 
sensing and responding to specific information being conveyed to the cell. While this 
cell-ECM interaction is determined by a group of proteins on the cell surface called 
“integrins,” cell-cell communication is determined by another group of proteins called 
“cadherins” (not discussed in this dissertation) (Chambers et al., 2002; Frixen et al., 
1991). Although these interactions are fairly complex, simply put, focal adhesion sites 
located on the edge of the cell house these integrins which form the link between the 
ECM present on the outside and the cytoskeleton present on the inside of the cell as 
described in Figure 1.4 (Hervy et al., 2006). This segment will touch on the roles of 
ECM, integrins and focal adhesions in the regulation of cellular features being studied in 
this dissertation. 
The ECM can be described as a heterogenous meshwork of fibrillar and 
nonfibrillar components which can be assembled into elaborate structures such as 
basement membranes and interstitial matrices that are composed of laminins, collagens 
and glycoproteins such as fibronectin, which in turn act as ligands for cell surface 
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receptors such as integrins (Dubash et al., 2009; Humphries et al., 2004). The integrated 
mechanics and dynamics between the cell and the ECM enables cells to control their 
shape, generate force, and ultimately remodel the surrounding ECM (Bershadsky et al., 
2003; Giancotti and Ruoslahti, 1999; Ingber, 2008; Janmey, 1998).  
A significant role for integrins in bone biology was first suggested in 1986 when 
antibodies raised against osteoclasts were shown to inhibit bone resorption in vitro 
(Chambers et al., 1986). ‘Integrins’ were first identified as trans-membrane proteins that 
are ‘integral’ to the link between the cell and the ECM in 1986, hence the name (Hynes, 
2004; Tamkun et al., 1986). These are comprised of an α subunit that is noncovalently 
bound to a β subunit, forming a large trans-membrane heterodimer, and consequently, 
may respond to cytoplasmic and extra cellular cues. To-date, 18α and 8β subunits are 
known to assemble in 24 different combinations of heterodimers which bind to distinct 
ECMs to determine outside-in and inside-out signaling in cells thereby regulating cell 
adhesion, survival, proliferation, migration and invasion (Hynes, 2002). To achieve so 
many functions, integrins can bind to multiple ligands and conversely, several ECMs can 
bind to multiple integrins by recognizing certain peptide sequences such as Arginine-
Glycine-Aspartic acid (RGD) (Humphries et al., 2004; Ruoslahti, 1996). However, 
binding of integrins to the ligand is not sufficient for a meaningful functional interaction; 
rather, it also requires activation of these integrin heterodimers by clustering on the cell 
surface and/or by inducing conformational changes in the receptors. Downstream to the 
stimulation of integrins, the activation of Rho GTPases regulates formation of stress 
fibers and focal adhesions thereby allowing cells to adhere, spread and migrate (Guo and 
Giancotti, 2004; Salsmann et al., 2006).  
14 
One of the most well characterized integrin-ECM interactions is that between 
α5β1 integrin and fibronectin (Nagae et al., 2012; Yang et al., 1999). In the case of 
hematological malignancies, the presence of fibronectin and its receptor in the bone and 
bone marrow suggest a vital role for these interactions in tumor-host signaling (Geiger et 
al., 2001; Wennerberg et al., 1996). Therefore, these interactions need to be evaluated in 
appropriate context for each malignancy. This dissertation attempts to evaluate the role of 
α5 integrin in regulating the cytoskeletal features and cell adhesion of Ewing sarcoma 
cells in vitro and in vivo in Chapter 5. 
These sites of cell-ECM interactions correspond to the area of the plasma 
membrane where actin bundles terminate and are called focal adhesions (Singer, 1979).  
The term “focal adhesion” was first coined to describe focused regions where the cell 
makes contact with the substratum and anchors the actin bundles. These are dense 
adhesion plaques on the edge of the cells visible by light and electron microscopy 
(Abercrombie et al., 1971; Heath and Dunn, 1978). Apart from structural contributions, 
focal adhesions convey information bidirectionally between cells and their surroundings. 
This is reflected in a recent report that observed integrin-based focal adhesions comprised 
of 156 molecules forming 690 potential interactions (Zaidel-Bar and Geiger, 2010). Such 
complex networking at these sites of cell adhesion vary based on the organism, tissue, 
cell and even spatio-temporally regulated in a cell during various stages of development 
and/or malignancy (Guo and Giancotti, 2004; Kumar and Weaver, 2009; Mitra and 
Schlaepfer, 2006). During these processes, the cells required to adhere and spread on the 
matrix, attach and detach efficiently for directed migration and possibly invade through 
the surrounding membrane. The cells therefore change the number and size of their focal 
adhesions and use the actin stress fiber network to generate enough extensile and 
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contractile forces based on the composition and stiffness of the matrix (Balaban et al., 
2001; Ingber, 2008; Mierke et al., 2008). In Chapter 4 of this dissertation, one such focal 
adhesion protein called zyxin is scrutinized in response to mechanical stimulation to 
affect actin stress fiber network.   
It should be noted that the cells and the surrounding ECM are interdependent on 
each other. For example, while the integrins on the cell surface assemble fibronectin into 
functional fibrillar matrix and orchestrate assembly of other ECM components, this well-
defined matrix in turn promotes cell adhesion, migration, signaling and regulation of 
cytoskeleton (Leiss et al., 2008). In Chapter 5 of this dissertation we investigate the 
contributions of adhesion proteins in general and two proteins zyxin and α5 integrin in 
particular, whose expression is regulated by EWS/FLI to affect the characteristics of 
Ewing sarcoma cells in vitro and in vivo in the context of an orthotopic mouse model.   
Zyxin: a focal adhesion protein 
One of the proteins in the list of downregulated targets of EWS/FLI was “zyxin,” 
an 84KDa focal adhesion protein that was identified 25 years ago. This protein was 
named based on the Greek word “zeuxis,” which means “joining” because it was first 
observed at the junction of actin stress fibers and focal adhesions (Beckerle, 1986). Zyxin 
is known to regulate actin assembly, possibly through its N-terminus by binding α-actinin 
(Crawford et al., 1992; Hirata et al., 2008). Zyxin also has nuclear export signals and 3 
LIM domains in its C-terminus (Schmeichel and Beckerle, 1994). Zyxin is a protein that 
responds to mechanical cues, such as cyclic stretch or changes in the internal or external 
environment of cells, in order to maintain cytoskeletal integrity and homeostasis (Hervy 
et al., 2006; Hoffman et al., 2006; Yoshigi et al., 2005). In Chapter 4, domain analysis of 
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zyxin suggests that zyxin harbors two functionally and spatially discrete domains, a 
localization domain and a reinforcement domain, to collectively influence actin stress 
fiber reinforcement in response to cyclic stretch.  
Zyxin recognizes sites of local stress and repair actin stress fiber break or thinning 
events by recruiting α-actinin protein and Vasodilator-stimulated phosphoprotein (VASP) 
to the sites of stress fiber damage (Smith et al., 2010). It has nuclear export signals, which 
when mutated can result in shuttling of zyxin into the cell nuclei from adhesion plaques 
(Hervy et al., 2006). Zyxin is actually the first focal adhesion protein that showed 
shuttling between nucleus and focal adhesion sites (Nix and Beckerle, 1997). Some 
studies have reported that zyxin can bind to a transcription factor in vitro, to influence 
osteoblast differentiation by shuttling between the nucleus and focal adhesion sites 
(Janssen and Marynen, 2006). Interestingly, zyxin along with its binding partners plays 
crucial role in regulating gene expression in two tissues, both of which need to be 
extremely responsive to mechanical cues, namely, smooth muscle and bone (Hervy et al., 
2006). Given the above information about zyxin’s role in mechano-sensitivity in bone or 
osteoblast differentiation, it was intriguing to us to further evaluate any potential part that 
zyxin may have in influencing growth and metastasis of a bone tumor, such as Ewing 
sarcoma. 
In addition to these features, zyxin has also been previously implicated by other 
researchers in Ewing sarcoma. CD99 – a key cell surface receptor that is often specific to 
Ewing sarcoma – functions through reorganization of the actin cytoskeleton, and zyxin 
was critical to cell adhesion and downstream signaling cascade following CD99 
engagement (Cerisano et al., 2004). It was subsequently reported that zyxin expression in 
Ewing sarcoma cells correlated with actin cytoskeletal rearrangements and that zyxin acts 
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as a tumor suppressor for Ewing sarcoma in a mouse model (Amsellem et al., 2005). 
These studies inspired my interest in understanding how zyxin could contribute to Ewing 
sarcoma cell morphology and cell behavior, such as cell adhesion and actin cytoskeleton 
in vitro and in tumor growth and progression in vivo.  
α5 Integrin: fibronectin receptor subunit 
α5β1 integrin was one of the first integrin heterodimers to be discovered (Tamkun 
et al., 1986). To date, 11 integrin heterodimers are known to bind fibronectin (Leiss et al., 
2008), but among these α5β1 integrin is considered to be crucial for assembly of thin and 
long fibronectin fibrils. Upon binding fibronectin, the α5β1 integrins pull out from focal 
adhesions and move along actin stress fibers towards the centre of the cell and form a 
new adhesion structure called fibrillar adhesions, such that the fibronectin fibrils are 
aligned with α5β1 integrins and F-actin filaments (Geiger et al., 2001; Ohashi et al., 
2002; Pankov et al., 2000; Zamir and Geiger, 2001). As multiple integrins can interact 
with many ECM molecules, in the absence of α5β1, short and thick fibronectin fibrils can 
be assembled by αvβ3 integrin. While α5β1 integrin binds fibronectin via RGD and 
PHSRN (Pro-His-Ser-Arg-Asn) sequences to give cells their fibroblast like morphology, 
αvβ3 integrin binds only using the RGD sequence (Truong and Danen, 2009). This kind 
of an integrin switching has been shown to affect both cell spreading and the kind of 
fibrillar and focal adhesions present in the cells. Only a double knockout of α5 and αv 
integrin can completely deplete formation of fibronectin fibrils (Yang et al., 1999).  
The expression of α5 integrin on the cell surface is often modulated to affect 
different processes during development, erythropoesis and several malignancies. 
However, based on the cell type and the malignancy, the role of α5β1 integrin could be 
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positively correlated (Caswell et al., 2008; Kawajiri et al., 2008; Qian et al., 2005) or 
negatively correlated (Schirner et al., 1998; Tani et al., 2003; Taverna et al., 1998) with 
tumor formation, cell migration and metastasis. Such observations emphasize the need to 
study the role of cell surface receptors like α5β1 integrins in appropriate cellular and 
environmental context. Ewing sarcoma mostly affects the bone and bone marrow of a 
patient, which are both rich in fibronectin matrix and therefore, studying the role of α5 
integrin with its corresponding matrix fibronectin could provide new insights into the 
tumor cell behavior. 
It was demonstrated that three genes in the cell adhesion pathway were modulated 
by triggering CD99 in Ewing sarcoma cells: zyxin (as described above), α5β1 integrin 
(described in this sub section) and integrin β8 precursors (not evaluated in this study) all 
of which have been associated with influencing cellular adhesion (Cerisano et al., 2004). 
In this dissertation we were able to investigate the contributions of two of these genes, 
zyxin and α5 integrin in Ewing sarcoma cell biology. 
Goals of this dissertation 
Molecular mechanisms regulating metastasis in nonepithelial cancers, 
mesenchymally-derived tumors or in tumors of uncertain origin are still not well 
characterized. This dissertation focuses on one such cryptic malignancy with uncertain 
histogenesis and aggressive biological behavior, Ewing sarcoma. Most of the research in 
this field is centered on understanding the transcriptome of the EWS/FLI fusion 
oncoprotein to identify and study critical targets required for pathogenesis of Ewing 
sarcoma.  The research described here is a step towards studying the mechanisms by 
which EWS/FLI mediates changes in tumor cell behavior such as cytoskeletal integrity, 
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cell morphology, cellular spreading and adhesion. This knowledge will provide valuable 
information about the specific cellular features that are critical to EWS/FLI dependent 
cellular pathogenesis. The work described here explores the contributions of two 
downregulated targets of EWS/FLI to Ewing sarcoma pathogenesis. These studies have 
been performed using a loss-of-function approach where retrovirally infected shRNA 
could knockdown the expression of endogenous EWS/FLI in patient-derived Ewing 
sarcoma cells.  This approach enabled us to address the impact of EWS/FLI expression 
on Ewing sarcoma cell behavior within its native cellular context more accurately, which 
was vital to this study.  
This dissertation describes my work in the following segments:  
i. Review of metastatic Ewing sarcoma. In this review, I highlight the role of 
tumor microenvironment in Ewing sarcoma. I provide a comprehensive 
analysis of the possible host-tumor interactions that could influence the 
metastatic behavior of Ewing sarcoma cells and guide their propensity to 
metastasize to lungs and other bones. 
ii. What is the impact of EWS/FLI expression on the behavior of tumor cells? In 
this segment, I provide evidence that EWS/FLI expression gives the cells their 
round cell morphology and compromises actin cytoskeleton, cell adhesion and 
cell migration. I present a model that suggests loss of cell adhesion is caused 
by the oncogenic event which could lead to early tumor dissemination and 
contribute to metastasis, while simultaneously forming Ewing tumors. 
iii. How does a focal adhesion protein sense cellular stress and remodel actin 
filaments?  In this collaborative study, we investigate the mechanism used by 
focal adhesion proteins, especially zyxin, to sense physical stress around the 
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cells and maintain or reinforce the actin stress fibers even in the presence of 
Rho inhibitors. This study was performed on fibroblasts but was vital in 
suggesting the possible role of adhesion proteins in regulating cytoskeletal 
features in Ewing sarcoma cells. 
iv. What is the role of downregulated targets of EWS/FLI, especially zyxin and α5 
integrin, in tumor cell behavior in vitro and in vivo? In Chapter 5 of this 
dissertation, I first describe how expression of zyxin and α5 integrin in Ewing 
sarcoma cells leads to different functional contributions to the actin 
cytoskeleton, cell adhesion and cell spreading despite their overlapping 
location in the cells. Also, I describe the orthotopic tibial mouse model that I 
developed to study the growth, progression and metastasis of Ewing sarcoma 
cells. I then used in vivo model to dissect the contributions of zyxin and α5 
integrin in regulating tumor progression and spontaneous metastasis of Ewing 














Figure 1.1: Metastatic Ewing sarcoma is a lethal disease. The 5-year overall survival 
rate of Ewing sarcoma patients is extremely poor when diagnosed with metastatic disease 
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Figure 1.2: Schematic diagram of the EWS/FLI fusion transcript. The amino-
terminal domain or NTD from wild-type EWS protein and the carboxyl-terminal domain 
containing the DNA-binding domain from the FLI protein translocate and fuse as shown 













Figure 1.3: Histopathology of Ewing sarcoma. Ewing sarcoma is characterized by the 
appearance of monomorphic small round blue cells when stained with Hematoxylin and 

























Figure 1.4: Spatial distribution of ECM, integrins and focal adhesions in cell. 
Integrins are transmembrane proteins localized at focal adhesion sites and transmit 
information between the ECM and the actin cytoskeleton or other places such as the 
nucleus in the cell, as represented in a cartoon (top) (Image is provided as a courtesy by 
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THE EWS/FLI ONCOGENE DRIVES CHANGES IN CELLULAR  
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The uncertain histogenesis and aggressive biological behavior of Ewing sarcoma 
has always been a subject of interest among clinicians and researchers alike. This 
malignant disease is driven by the fusion oncogene EWS/FLI which is necessary for 
transformation. The role of basic cellular features like actin cytoskeleton and focal 
adhesion sites are not very well understood in Ewing sarcoma tumor growth and 
metastasis. Here, we have used the RNAi-based silencing of EWS/FLI oncogene that 
result in dramatic cytoskeletal changes and reduced cellular spreading and adhesion, 
potentially through downregulation of the genes regulating these cellular features. 
Microarray analysis revealed hundreds of such genes that are associated with focal 
adhesion proteins, ECM-receptor interactions and cell adhesions. Our study demonstrates 
that focal adhesion protein zyxin and α5 integrin are downregulated by EWS/FLI to 
compromise the actin cytoskeleton, cell adhesion and, cell spreading of Ewing sarcoma 
cells as revealed by immunofluorescence microscopy. We hypothesize that EWS/FLI 
mediated changes in these cellular features facilitates cell transformation. To test this, the 
current study establishes an intratibial orthotopic mouse model and shows successful 
Ewing sarcoma tumor growth, progression and metastasis in NOD/SCID mice. To our 
knowledge, this is the first report of spontaneous metastasis to lungs and other bones 
from a primary Ewing sarcoma tumor in the mouse tibia. Using this mouse model we 
characterized the tumor progression and metastasis by Ewing sarcoma cells engineered to 
reexpress zyxin or α5 integrin or both zyxin and α5 integrin. In this mouse model the rate 
of tumor growth significantly decreases when both zyxin and α5 integrin are reexpressed 
in Ewing sarcoma cells, but the rate of metastasis to lungs is significantly higher when α5 




adhesion proteins is required for tumor progression, but could compromise tumor cell 
metastasis. The current study highlights the contributions of adhesion proteins (zyxin and 
α5 integrin) in modulating cell-ECM interactions, actin cytoskeleton, cell adhesion and 
spreading to achieve small round cell morphology and guiding tumor progression and 
metastasis in Ewing sarcoma. 
Introduction 
Ewing sarcoma is a round-cell malignant neoplasm of the bone that typically 
affects adolescents and young adults. It usually develops in the diaphysis or metaphysis 
of long bones, most commonly in femur, tibia and humerus (Kimber et al., 1998; Spraker 
et al., 2012).  Ewing sarcoma is an aggressive cancer that grows rapidly and metastasizes 
to lungs and bones (Karosas, 2010). Treatment of apparently localized primary tumors 
involves surgery and chemotherapy. Despite these interventions, the vast majority of 
patients relapse even after definitive surgical removal of the primary tumor, illustrating 
the fact that most patients have occult disseminated disease upon presentation 
(McAllister and Lessnick, 2005; Spraker HL et al., 2012). Patients with metastatic or 
recurrent disease face poor prognosis with less than 15% 5-year survival rate. Knowledge 
of the molecular mechanisms that determine Ewing sarcoma cell behavior will be crucial 
in understanding disease progression.  
Ewing sarcoma is caused by a reciprocal chromosomal translocation involving the 
EWSR1 gene on chromosome 22 and a member of the FLI gene on chromosome 11 
(Delattre et al., 1992; Turc-Carel et al., 1988).  In approximately 85% of cases, a 
t(11;22)(q24;q12) translocation results in the expression of chimeric transcription factor 




portion of FLI-1 that includes a DNA-binding domain (Aurias et al., 1984; Delattre et al., 
1992; Lessnick et al., 1995; May et al., 1993a). EWS/FLI acts as a master transcriptional 
regulator that modulates the expression of several hundred genes. Several upregulated 
targets of EWS/FLI have been extensively studied including NKX2.2, NR0B1 and 
Caveolin1 (Kinsey et al., 2006; Owen et al., 2008; Tirado et al., 2006).  Although 
predicted to aberrantly activate transcription, EWS/FLI also causes repression of 
hundreds to thousands of genes (Kinsey et al., 2006; Owen et al., 2008; Smith et al., 
2006).  With a few exceptions (Borinstein et al., 2011; Herrero-Martin et al., 2009; 
Mateo-Lozano et al., 2003), the downregulated targets of EWS/FLI have not been 
extensively  characterized, even though the repression of specific gene expression could 
lead to loss of key regulators of normal cell growth and behavior.  
Recent studies suggest that EWS/FLI is not only required for tumorigenesis, but 
also modulates key cellular properties such as cell adhesion, motility and invasion 
(Amsellem et al., 2005; Cerisano et al., 2004; Chaturvedi et al., 2012). For example, 
RNA interference based knockdown of EWS/FLI expression revealed that EWS/FLI 
expression promotes loss of tumor cell adhesion (Chaturvedi et al., 2012). EWS/FLI - 
mediated regulation of adhesion genes could affect two stages of Ewing sarcoma 
metastasis: tumor cell dissemination and/or readhesion of these cells at a secondary site 
for effective colonization. Here, we identify specific EWS/FLI target genes that regulate 
the tumor cell adhesion to extracellular matrix and contribute towards maintenance of 
actin cytoskeleton. In the current study we investigate the contributions of two EWS/FLI 
targets, zyxin and α5 integrin, to the actin cytoskeleton, cell spreading and adhesion of 
Ewing sarcoma cells. We extend the results from in vitro studies into an experimental 




observed in patients, including rapid formation of osteolytic tumors and aggressive 
metastasis to lungs and other bones.    
Results 
EWS/FLI expression compromises the cytoskeleton of Ewing sarcoma cells   
The cell of origin that gives rise to Ewing sarcoma has not yet been definitively 
identified (Cavazzana et al., 1987; Ewing, 1921; Jedlicka, 2010; Kovar, 2005; Tirode et 
al., 2007). Consequently, the approach of ectopic EWS/FLI expression as a way to model 
oncogene impact on cell behavior is fraught with difficulty, owing to the uncertain effect 
of inappropriate cellular context (Braunreiter et al., 2006; Owen and Lessnick, 2006). To 
circumvent this challenge, we studied how the EWS/FLI oncoprotein influences cellular 
behavior by using an RNA interference approach to knockdown EWS/FLI expression in 
patient-derived Ewing sarcoma cells (A673 and EWS502). 
We used retrovirally-encoded short hairpin RNA directed against EWS/FLI 
transcripts to knockdown the expression of EWS/FLI (EWS/FLI RNAi) and RNA 
interference against luciferase served as Control RNAi and compared their cellular 
behavior. Knockdown of EWS/FLI expression in multiple human Ewing sarcoma cell 
lines resulted in dramatic effects on cell phenotype including alterations in adhesion and 
motility (Chaturvedi et al., 2012). In an effort to provide an extracellular matrix ligand 
that is prominent in bone, the cells were plated on fibronectin (Rodan and Rodan, 1997). 
Ewing sarcoma cells displayed a profound cytoskeletal deficit (Figure 5.1A). Both A673 
cells and EWS502 cells appeared small and poorly spread, with thin and short actin stress 
fibers. In contrast, when EWS/FLI expression was knocked down by RNA interference, 




they exhibited pronounced adhesion and spreading to the fibronectin substratum and 
displayed robust actin stress fibers.  These results illustrated a profound effect of 
EWS/FLI expression on adhesion and cytoarchitecture, prompting us to explore the 
mechanism by which EWS/FLI influences these phenotypic attributes of the tumor cells. 
 EWS/FLI is a transcription factor that modulates the expression of hundreds to 
thousands of genes (Owen et al., 2008). To identify candidate targets of EWS/FLI that 
might influence adhesion and cytoarchitecture, we analyzed a previously published 
microarray analysis of EWS/FLI regulated genes (Owen et al., 2008). Selection of genes 
whose expression was decreased at least 1.8 fold by EWS/FLI revealed 222 genes that 
were downregulated by EWS/FLI by this criterion. Kyoto Encyclopedia of Genes and 
Genomes (KEGG) analysis revealed that the top three classes of genes downregulated by 
EWS/FLI were those encoding focal adhesion proteins, modulators of extracellular 
matrix and receptor interactions, and regulators of the actin cytoskeleton (Table 5.1), 
consistent with the major cellular phenotypes we observed by microscopic analysis of 
cells in Figure 5.1A. Inspection of the EWS/FLI downregulated genes revealed that more 
than one-third would be expected to influence the actin cytoskeleton, cell-matrix 
communication, or cell adhesion and migration based on their annotated functions 
(Supplemental Table S.1). The largest single class of genes downregulated by EWS/FLI 
expression encodes focal adhesion proteins. Focal adhesions are regions of the cell 
surface specialized for cell-matrix adhesion and transmembrane communication, known 
to convey information about extracellular matrix composition, as well as mechanical 
stress to the cell interior. Focal adhesions are themselves complex multicomponent 
structures with over 100 known protein constituents (Geiger and Yamada, 2011; Zaidel-




From the list of genes that are down-regulated by EWS/FLI, we selected the genes 
encoding zyxin and α5 integrin for further study because of their known influence on 
cytoskeleton and cell-matrix interactions. Zyxin is an important regulator of the actin 
cytoskeleton that is required for maintenance and repair of actin stress fibers (Hoffman et 
al., 2012; Smith et al., 2010; Yoshigi et al., 2005). Importantly, zyxin was previously 
implicated as a regulator of cytoskeletal function in Ewing sarcoma models (Amsellem et 
al., 2005; Cerisano et al., 2004). Integrins are transmembrane α5 heterodimeric receptors 
for extracellular matrix that are critical for cell-substratum adhesion as well as stress fiber 
anchorage and integrity (Campbell and Humphries, 2011; Hynes, 2002; Lotz et al., 
2000). α5 integrin is a known modulator of cell adhesion, migration and cell-matrix 
communication that dimerizes with α5 integrin subunit to confer adhesion to fibronectin 
(Gupton et al., 2012; Margadant et al., 2011; Mostafavi-Pour et al., 2003; Nagae et al., 
2012). Fibronectin expression is also reduced in EWS/FLI-expressing cells (Supp. Table 
S.1), consistent with the proposal that the EWS/FLI oncogene acts, at least in part, by 
abrogating cell-matrix adhesion and the associated actin cytoskeleton.  
Validating the microarray findings, Western immunoblot analysis comparing the 
protein complements in control and EWS/FLI knockdown cells, revealed that both zyxin 
and α5 integrin are downregulated ~two-fold by EWS/FLI expression (Figure 5.1B). 
Evidence that the RNA interference was effective in abrogating EWS/FLI expression is 
shown in Figure 5.1B in which FLI1 antibody detects reduced EWS/FLI fusion protein. 
Tubulin expression serves as a surrogate for cell number and controls for equivalent 




Reexpression of zyxin and α5 integrin in Ewing sarcoma cells influences  
the actin cytoskeleton, cell adhesion and spreading 
To study the impact of reduced expression of zyxin and α5 integrin in Ewing 
sarcoma, we reexpressed these downregulated targets in patient-derived Ewing sarcoma 
cells using retrovirus to program the cells to express these cDNAs of interest. As can be 
seen in Figure 5.1C, by Western immunoblot analysis, we detect increases in zyxin 
and/or α5 integrin.  Expression of these proteins does not detectably alter the levels of 
EWS/FLI in the cells, as detected with anti FLI1 antibody.   
Although EWS/FLI affects the expression of hundreds of genes, the reexpression 
of just one or two of these, zyxin and/or α5 integrin, in the Ewing sarcoma cells resulted 
in dramatic phenotypic alterations in the cells.  Importantly, these genes induced distinct 
alterations in cell morphology and cytoarchitecture.  Compared to the parental A673 cells 
infected with the empty retroviral vector, which were poorly spread and exhibited only 
rudimentary stress fibers (Figure 5.1D), Ewing sarcoma cells programmed to express 
zyxin displayed a profound elaboration of actin stress fibers, with an increase in cell 
spreading as well (Figure 5.1E).  Expression of α5 integrin alone appeared to improve 
cell spreading without resulting in enhancement of actin cytoskeletal arrays (Figure 
5.1F). When these proteins were coexpressed, the Ewing sarcoma cells are marked by 
both well formed actin stress fibers and enhanced cell spreading (Figure 5.1G). Similar 
results were obtained in both A673 and EWS502 cells (data not shown).  
Higher magnification and quantitative analysis of these initial findings confirmed 
the significant and unique impacts of zyxin and α5 integrin on Ewing sarcoma cell 
morphology and cytoarchitecture (Figure 5.2).   The cells were double labeled with 




mark focal adhesions (Figures 5.2E-H).  The size (Figure 5.2I) and number (Figure 5.2J) 
of focal adhesions was quantitated for each condition.  Knockdown of EWS/FLI 
expression in Ewing sarcoma cells resulted in a statistically significant increase in the 
average focal adhesion size from 1.3 µm2 to 1.8 um2 (Figure 5.2I). Reexpression of either 
zyxin, α5 integrin, or both zyxin and α5 integrin restored the size of paxillin-rich focal 
adhesions to a level that is not statistically different from what is observed when 
EWS/FLI is knocked down in Ewing sarcoma cells by RNAi (Figure 5.2I).   
Ewing sarcoma cells or those with control RNAi had fewer focal adhesions (~50 
per cell) compared to cells in which EWS/FLI expression was knocked down, which 
displayed an average of 177 focal adhesions per cell (Figure 5.2J). Expression of zyxin 
and/or α5 integrin in Ewing sarcoma cells resulted in a statistically significant increase of 
focal adhesion number (Figure 5.2J).  Interestingly, however, zyxin expression had a 
much more significant impact on focal adhesion number than did expression of α5 
integrin.  For example, expression of α5 integrin led to moderate increase in number of 
focal adhesions from an average of 50 to 70 per cell (Figure 5.2J).  However, expression 
of zyxin alone or α5 integrin led to dramatic increase in the focal adhesion number to 
more than 150 focal adhesions per cell (Figure 5.2J), highlighting the differential impact 
of zyxin and α5 integrin on establishment of number of focal adhesions. 
Given the established link between focal adhesion development and cell spreading 
(Salsmann et al., 2006; Smilenov et al., 1999), the increased focal adhesion size and 
number observed upon reexpression of zyxin and/or α5 integrin was consistent with low 
magnification analysis which suggested that reexpression of either zyxin or α5 integrin 
enhanced cell spreading.  To test this possibility quantitatively, we measured the areas of 




Expression of zyxin and/or α5 integrin resulted in statistically significant increase in cell 
spreading, illustrated by increased cell area (Figure 5.2K).  Measured cell area more than 
doubled from 950 µm2 for Ewing sarcoma cells harboring empty vector to >1500 µm2 for 
cells expressing the adhesion proteins (Figure 5.2K).  Reexpression of zyxin induced a 
more robust spreading response than what occurred with reexpression of α5 integrin, 
although both displayed more extensive cell spreading that the parental Ewing sarcoma 
cells.  Interestingly, the cell area for Ewing sarcoma cells with knockdown of EWS/FLI 
(~2200 µm2) was indistinguishable from the average area of cells expressing either zyxin 
alone or in combination with α5 integrin, illustrating that reexpression of zyxin is 
sufficient to fully rescue the cell spreading deficit observed in Ewing sarcoma cells.  
The increased cell spreading and focal adhesion assembly was associated with 
enhanced adhesion, as measured in a quantitative, short time course cell adhesion assay 
(Figure 5.2L). In this 2 hour adhesion assay the cells were allowed to adhere to an 
uncoated plastic tissue culture dish.  Knockdown of EWS/FLI expression resulted in a 
statistically significant 2-fold increase in cell adhesion (Figure 5.2L). Reexpression of α5 
integrin alone or with zyxin enhanced cellular adhesion comparable to cells in which 
EWS/FLI expression was knocked down by RNAi.  Although Ewing sarcoma cells 
reexpressing zyxin also increased cell adhesion, the effect was not as dramatic as in the 
presence of α5 integrin (Figure 5.2L).  The profound, yet differential capacity of zyxin 
and α5 integrin to restore cell adhesion, spreading, actin cytoskeleton and focal adhesion 




Intratibial orthotopic mouse model for Ewing sarcoma recapitulates  
features of the human disease 
The ultimate goal of our studies was to understand both the critical cellular 
mechanisms that are compromised in EWS/FLI-transformed cells and to decipher the 
consequences of these alterations for tumor biology. To test whether increasing cellular 
adhesion by the reexpression of zyxin and α5 integrin in Ewing sarcoma cells would 
affect tumor cell behavior in vivo, we first established an orthotopic xenograft model that 
faithfully replicates key aspects of Ewing sarcoma behavior. In brief, we injected A673 
Ewing sarcoma cells that were suspended in extracellular matrix (Matrigel) into the right 
tibias of NOD/SCID immunodeficient mice.  The tumor cells were programmed to 
constitutively express luciferase, enabling continuous detection of viable cells in situ. 
Tumor growth and progression, including histopathology, osteolysis, and metastasis, 
were systematically monitored (Figure 5.3A).  
Under our experimental conditions, tumors grew rapidly and were highly 
osteolytic. Most of the mice (14 out of 15) formed tumors in the injected tibia within four 
weeks. Using in vivo luciferase imaging we observed aggressive growth of these tumors 
between weeks 3 and 4 (Figure 5.3B). Tibial radiographs revealed extensive osteolysis 
(Figure 5.3C) a characteristic of Ewing sarcoma progression in human patients. 
Radiographic analysis revealed that 85% of mice displayed cortical bone destruction and 
massive bone loss by week 4, warranting a classification of grade 3 or 4 osteolysis 
(Figure 5.3D). Ewing sarcoma is distinguished by its small round blue cell morphology 
when tissue biopsy sections are stained with hematoxylin and eosin (H&E) as well as 
distinct membrane labeling with antibodies directed against CD99, a transmembrane 




1991; Fellinger et al., 1991; Perlman et al., 1994). Consistent with features observed in 
clinical samples, The histological presentation and positive CD99 staining of Ewing 
sarcoma cells in the mouse model were indistinguishable from what is observed in human 
patient samples (Figure 5.3E), illustrating preservation of key morphological properties 
of the human tumor cells in the context of the murine host. 
In patients, Ewing sarcoma arises in bone and has a propensity to metastasize to 
lung and other bones (Arndt and Crist, 1999; Spraker et al., 2012). This feature is also 
preserved in our mouse orthotopic model (Figure 5.3F-G). In vivo imaging of the 
luciferase tagged Ewing sarcoma cells in the mice revealed that half exhibited positive 
signal in the chest area, suggesting potential metastasis to the lungs. Upon dissection and 
histopatholgical analysis, lungs that were luciferase-positive exhibited small round blue 
cells by H&E staining and positive anti-CD99 labeling, confirming the presence of 
metastatic Ewing sarcoma cells (Figure 5.3F).  Luciferase imaging of the mouse carcass 
revealed metastasis to other sites, such as the left tibia or upper limb and occasionally to 
ribs and spine (Figure 5.3G). The development of a robust mouse model system for 
Ewing sarcoma that recapitulates key clinical features of the human disease set the stage 
for studies of the impact of EWS/FLI dependent gene regulation in vivo. 
EWS/FLI dependent repression of zyxin and α5 integrin expression  
enhances anchorage independent growth of Ewing sarcoma cells 
To probe the impact of EWS/FLI-dependent repression of zyxin and α5 integrin 
expression, we introduced Ewing sarcoma cells that were engineered to reexpress one or 
both of these proteins into recipient mice via intratibial injection, as described above, and 
compared the growth of the resulting primary tumors with those derived from parental 




reexpression, or zyxin plus α5 integrin reexpression), 90-100% of the mice formed 
luciferase positive tumors within 4 weeks after intratibial injection (Figure 5.4A). 
Histological analysis of tissue sections taken at week 4 revealed that all of the tumors 
exhibit small round blue cell morphology characteristic of Ewing sarcoma and were 
CD99-positive by immunohistochemistry (Supp Fig S.1). Light microscopic examination 
revealed no differences among the four tumor groups. Likewise, significant osteolysis 
(>Grade 3) was evident in radiographs of the affected tibias at 4 weeks for tumors 
derived from all four cell variants (Figure 5.4B).  
Although all four tumor cell variants formed palpable tumors and osteolytic 
lesions, in vivo luciferase based imaging of tumors derived from A673 cells coexpressing 
zyxin and α5 integrin revealed slower tumor growth than tumors derived from either 
parental A673 cells or cells expressing just one of the transgenes (Figure 5.4C). This 
observation suggests that EWS/FLI mediated downregulation of zyxin and α5 integrin 
synergistically facilitates tumor growth.  
The reduction in primary tumor growth by Ewing sarcoma cells that expressed 
both zyxin and α5 integrin raised the possibility that reexpression of these two focal 
adhesion proteins might impact cell proliferation rate.  To test this possibility directly, we 
measured cell growth in culture (Figure 5.4D).  The three reexpression lines displayed 
growth curves that were indistinguishable from that of the parental A673 Ewing sarcoma 
cells, indicating that anchorage-dependent cell proliferation was not detectably influenced 
by altering zyxin or α5 integrin levels.  In striking contrast, simultaneous reexpression of 
zyxin and α5 integrin in A673 cells results in ~40% reduction in the number of cell 
colonies in a soft agar tranformation assay, whereas neither individual protein resulted in 




of viable tumor cells by in vivo luciferase monitoring in Figure 5.4C, coexpression of 
zyxin and α5 integrin synergistically retards cell growth in soft agar.  In particular, the 
reduction in zyxin and α5 integrin that occurs in response to EWS/FLI expression 
enhances the cells’ capacity to proliferate under anchorage-independent growth 
conditions.  
EWS/FLI-dependent repression of α5 integrin, expression  
abrogates metastatic lung colonization  
Because of the impact of cell adhesion in establishing metastatic potential 
(Arjonen et al., 2011; Patel et al., 2011), it was of interest to evaluate whether repression 
of zyxin and/or α5 integrin expression influences this process.  The tibial injection model 
we developed, in which metastasis of Ewing sarcoma cells follows the pattern of sites 
observed clinically in patients, enabled us to probe the roles of zyxin and/or α5 integrin in 
the spatial and temporal regulation of metastasis. A673 parental Ewing sarcoma cells, or 
cells engineered to reexpress zyxin and/or α5 integrin were introduced into recipient mice 
by intratibial injection and were followed by weekly in vivo luciferase imaging for 4 
weeks, to evaluate the rate at which metastasis (positive chest signal) developed for each 
A673 sarcoma cell variant (Figure 5.5A).  Interestingly, mice injected with Ewing 
sarcoma cells that reexpressed α5 integrin alone or in concert with zyxin revealed 
positive luciferase signal in the chest earlier than mice injected with Ewing sarcoma cells 
harboring empty vector or zyxin only (Figure 5.5A). By 3 weeks after intratibial 
injection, intravital imaging revealed evidence of tumor burden beyond the initial site of 
tumor cell injection, for Ewing sarcoma cells expressing empty vector.  At this time, 
differential levels of metastasis were already evident for the different molecular variants 




harboring the parental A673 tumor cells or A673 cells programmed to reexpress zyxin, 
whereas tumor cells programmed to reexpress α5 integrin either alone or with zyxin, 
more than tripled the frequency of evident metastases.  By week 4, differences in the 
behavior of the tumor cell variants was further accentuated, with metastasis evident in 
approximately 90-100% of the animals injected with A673 sarcoma cells that reexpressed 
α5 integrin alone or with zyxin, and 40% of animals injected with A673 cells 
programmed to reexpress zyxin, and 50% of animals injected with parental A673 cells 
(Figure 5.5A-5.5B) 
We examined the propensity of the metastatic tumor cells to colonize the lung, a 
common site of metastasis in human Ewing sarcoma patients. When animals were 
sacrificed at 4 weeks post injection, lungs were isolated by dissection, examined 
macroscopically, and prepared for histological staining and immunohistochemistry. 
Although dissected lungs had macroscopically visible metastatic lesions, lungs derived 
from mice injected with cells expressing α5 integrin either alone or with zyxin were 
extensively riddled with lesions at high frequency (Figure 5.5C). Stained sections of lung 
tissue displayed small round blue cells that were positive for the Ewing sarcoma marker, 
CD99 (Figure 5.5C).  When dissected bones and organs of sacrificed mice were 
examined for presence of metastasis by luciferase imaging, mice across all four groups 
showed presence of bone metastasis in addition to lung metastasis (Figure 5.5D).  
Common sites for presence of bone metastasis were uninjected leg, upper limb, spine and 
ribs. These results illustrate that in our model EWS/FLI-mediated downregulation of 
zyxin and α5 integrin still led to detectable metastasis to lungs and bones, consistent with 




Reexpression of adhesion proteins in Ewing sarcoma cells increases  
the cellular adherence to lung parenchyma in vivo    
To test if the increased adhesion of Ewing sarcoma cells reexpressing zyxin 
and/or α5 integrin (as in Figure 5.2L) could explain the high incidence of lung lesions in 
our mouse experiments, we used a lung colonization assay wherein we differentially 
labeled Ewing sarcoma cells harboring empty vector using the red lipophilic dye (DiI), 
and cells reexpressing zyxin and/or α5 integrin were marked green using the lipophilic 
dye (DiO). An equal mix of control cells and cells reexpressing zyxin and/or α5 integrin 
were injected into the bloodstream of immunodeficient mice via tail vein (Padua et al., 
2008). Lungs were harvested 24 hours post injection and scanned for the presence of 
fluorescently labeled red or green cells adhering to lung parenchyma (Figure 5.6A-C). 
Although Ewing sarcoma cells adhered to the lung tissue, they exhibited higher adhesion 
when these tumor cells reexpressed zyxin and/or α5 integrin. This was clearly indicated 
by increased ratio of green cells in the lung parenchyma compared to red cells (Figure 
5.6). Expression of zyxin (Figure 5.6A), α5 integrin (Figure 5.6B), or both zyxin and α5 
integrin (Figure 5.6C) significantly increased adhesion of cells to lung parenchyma 
(Figure 5.6D). Therefore, Ewing sarcoma cells expressing zyxin and/or α5 integrin 
exhibited high adhesion in our in vitro and in vivo experiments, suggesting that EWS/FLI 
mediated downregulation of zyxin and α5 integrin reduces tumor cell adhesion which 
could determine Ewing sarcoma cell behavior and metastasis. 
Discussion 
Nearly all cases of Ewing sarcoma harbor the t(11;22) chromosomal translocation 
and are micrometastatic at presentation. However, very little is understood about how 




complex cell behaviors that dictate Ewing sarcoma tumor progression and metastasis 
(May et al., 1993b; Owen et al., 2008; Smith et al., 2006). In order to dissect the 
mechanism by which EWS/FLI affects tumor cell properties such as cytoarchitecture and 
cell adhesion, we used patient-derived Ewing sarcoma cell lines to identify the 
misregulated genes responsible for the tumor phenotypes. 
It should be noted that this is the first study that examines multiple downregulated 
targets of EWS/FLI to evaluate tumor cell behavior, revealing that the knockdown of 
EWS/FLI leads to compromised cytoskeletal integrity and adhesiveness of Ewing 
sarcoma cells.  Analysis of the gene expression signature of EWS/FLI using a previously 
published microarray (Owen et al., 2008) showed that the targets that were most 
downregulated by EWS/FLI were focal adhesion proteins, extracellular matrix (ECM)-
receptor proteins and the regulators of actin cytoskeleton.  We therefore proposed that 
such genes could play a critical role in modulating tumor cell adhesion, cell spreading, 
and interaction of tumor cells with their environment, hence affecting tumor progression 
and metastasis. These processes have not been well studied in Ewing Sarcoma, but could 
explain unique cellular properties of this micrometastatic tumor. Here, we have dissected 
the impact of two such EWS/FLI downregulated targets: zyxin (a focal adhesion protein) 
and α5 integrin which, along with β1 integrin subunit, forms the receptor for binding 
fibronectin - a prominent bone matrix component. We reexpressed these proteins in 
patient-derived Ewing sarcoma cells either alone or in combination with each other to 
identify the unique and distinct contributions of zyxin and α5 integrin in Ewing sarcoma 
biology. 
We propose that downregulation of these adhesion proteins and inhibition of the 




cells. In the current study we show that reexpression of α5 integrin in the small round 
Ewing sarcoma cells improves cell spreading which could be attributed to increased size 
of focal adhesions, but when zyxin is reexpressed in these cells, either alone or along 
with α5 integrin, dramatic change in the actin cytoskeleton coincides with increased cell 
spreading. This difference could be attributed to the increased number and size of focal 
adhesions required for stabilizing the actin stress fiber network in cells.  We also report 
an increase in the number of focal adhesions when zyxin is expressed in cells, either 
alone or with α5 integrin to greatly foster robust actin stress fiber network in Ewing 
sarcoma cells with a modest improvement in cell adhesion. This compromised cell 
adhesion due to downregulation of zyxin and disruption of α5 integrin-fibronectin 
interaction could be critical for Ewing sarcoma tumor growth, as observed by reduction 
in number of colonies in soft agar transformation assays when both zyxin and α5 integrin 
are reexpressed in Ewing sarcoma cells. Interestingly, similar to increased cell adhesion 
and well spread fibroblast-like morphology seen in Ewing sarcoma cells reexpressing α5 
integrin, it is well known that expression of α5β1 integrin promotes fibroblast like 
morphology of cells (Truong and Danen, 2009). This observation contributes to the 
increasing body of evidence that mesenchymal cells could be the cell of origin for Ewing 
sarcoma (Riggi et al., 2008; Tirode et al., 2007), potentially by disrupting the interaction 
between α5 integrin and fibronectin in the bone. 
  Knowing that bone is the most common site for occurrence of Ewing sarcoma, in 
the present study, we injected the patient derived Ewing sarcoma cells into the mouse 
tibia to study tumor growth and metastasis of Ewing sarcoma from long bones of mice. 
This mouse model recapitulated several features of the human disease by showing rapid 




and lungs but not to liver or other vital organs. To our knowledge, this is the first report 
that shows spontaneous metastasis of Ewing sarcoma from the primary boney site to 
other bones. Using RT-PCR analysis we detected Ewing sarcoma cells in the blood (data 
not shown), confirming that these cells metastasized hematogenously similar to that in 
human patients. Observations like the tissue specific metastasis of Ewing sarcoma to lung 
and bones but not the liver, despite using blood circulation for metastasis highlight the 
role of tumor microenvironment in Ewing sarcoma (Kerbel, 1995; Mundy, 2002). We 
therefore consider this mouse model highly relevant for studying Ewing sarcoma. For 
example, this mouse model will adequately represent the interaction of α5β1 integrin to 
the fibronectin matrix, which is so abundantly present in the bone.  
Reexpression of α5 integrin and zyxin together (but not alone) in Ewing sarcoma 
cells, reduces the rate of growth for tibial tumors, similar to loss of transformation seen in 
soft agar assays, but also had increased rate of metastasis. Interestingly though, 
reexpression of α5 integrin alone or in combination with zyxin , led to early metastasis of 
Ewing sarcoma cells to the chest area consequently leading to larger lesions in the mouse 
lungs. These results raise an interesting concept that EWS/FLI mediated repression of 
zyxin and α5 integrin affects cellular morphology and cell adhesion to facilitate tumor 
cell growth and transformation, but the same repression also appears to compromise at 
least one step of metastasis, such as the ability of these cells to adhere and colonize at a 
secondary site, such as lungs in the current mouse model. Such uncoupling of tumor 
progression and metastasis by an oncogene has been suggested previously by other 
researchers as well (Bernards and Weinberg, 2002).  
The reasons for the micrometastatic nature of Ewing sarcoma cells could be 




cell dissemination (Chaturvedi et al., 2012), or regulate expression of EWS/FLI based on 
growth factors in the tumor microenvironment (Girnita et al., 2000) or even be correlated 
to size of the primary tumor (Rodriguez-Galindo et al., 2008). Based on these findings, as 
the solid tumor grows, the tumor microenvironment could induce changes in gene 
expression or matrix availability. It has been shown that microenvironmental changes 
such as hypoxia increases the expression of α5 integrin, which in turn increases the 
adhesion of cells to fibronectin affecting downstream signaling and hence cell metastasis 
(Indovina et al., 2008). Such a situation is duplicated in our experiments with 
reexpression of α5 integrin (either alone or with zyxin) in Ewing sarcoma cells, and that 
could explain early metastasis as seen in mice injected with these cell variants. Once in 
circulation, the cells show increased adhesion to lung parenchyma, as seen in the in vivo 
lung colonization assay by increasing cell adhesion.  
The present study identifies a potentially crucial role of actin cytoskeleton and 
focal adhesion based cell-ECM interactions in Ewing sarcoma growth and metastasis. 
Higher expression of α5β1 integrin in certain cancer cells improves the actin 
cytoskeleton, increases cell spreading and improves the interaction of α5β1 expressing 
cells to the available fibronectin and collagen matrix, thereby increasing contractile 
forces and cellular invasion (Mierke et al., 2011).  In our study, we found that expression 
of zyxin significantly improves actin cytoskeleton and makes a modest contribution to 
cell adhesion, whereas expression of α5 integrin improves cell adhesion and spreading 
without much contribution to the actin cytoskeleton. When these proteins are expressed 
together, the Ewing sarcoma cells show higher cell adhesion, spreading and a strong 
stress fiber network. We therefore propose that reexpression of zyxin improves the actin 




size of focal adhesions, and expression of α5 integrin improves the interaction to 
fibronectin matrix present in the bone.  
Our findings illustrate that the causative oncogene for Ewing sarcoma 
simultaneously affects both cell proliferative capacity as well as a wide range of cellular 
phenotypes that could influence tumor cell dissemination or metastatic colonization. 
Understanding how EWS/FLI mediated downregulation of adhesion genes, integrins and 
cytoskeletal proteins affects early and late tumor cell dissemination or affects tumor cell 
adhesion and colonization at secondary sites, through its effects on the actin cytoskeleton 
and cell adhesion invasion and metastasis is critical to understanding the micrometastatic 
nature of this disease. The loss in cellular adhesion observed in EWS/FLI transformed 
cells could prevent formation of multilayer foci required for formation of solid tumors 
(Taverna et al., 1998, Hynes 1998),  and it could simultaneously promote early 
dissemination of tumor cells (Chaturvedi et al., 2012). We also suggest that Ewing 
sarcoma cells and/or EWS/FLI expression is especially sensitive to microenvironmental 
cues and through changes in downstream gene expression influences tumor cell behavior 
to establish successful metastatic lesions. Evaluating the effect of adhesion proteins on 
the rate of tumor cell dissemination will be the focus of future studies in which a higher 
degree of temporal resolution and detection of circulating tumor cells is possible.  
These studies illustrate the need to study tumors in their relevant 
microenvironment to understand how the tumor cell behaviors observed in cell culture 
experiments affect disease progression. In addition, our findings demonstrate the 
existence of ‘tradeoffs’ that occur within oncogenic programs.  For example, in the case 
of Ewing sarcoma, downregulation of zyxin and α5 integrin expression confers an 




at the same time reducing the capacity for metastatic lung colonization.  These findings 
illustrate the multifactorial complexity of tumor biology and remind us that not all gene 
expression changes observed in tumors are advantageous for all aspects of tumor 
initiation and progression. 
Materials and Methods 
Reagents and antibodies 
  Antibodies were used for Western immunoblots, indirect immunofluorescence 
microscopy, and inmmunohistochemistry as per manufacturer’s instructions: paxillin 
mouse antibody (Transduction Laboratories  P13520), FLI-1 rabbit antibody (AbCam 
15289), zyxin rabbit antibody (Beckerle Lab B71), α5 integrin (BD Bioscience), β-actin 
AC-74 mouse antibody (Sigma-Aldrich),  β-tubulin mouse antibody (Developmental 
Studies Hybridoma Bank 12G10), CD99 (clone 0-13) mouse antibody (Signet #620-01). 
Secondary antibodies were HRP-conjugated antibodies for immunoblots (GE 
Healthcare), the Alexa-Fluor antibodies and phalloidin for microscopy (Molecular 
Probes/Invitrogen), and biotinylated rabbit antimouse antibody (Dako #E0413) for 
immunohistochemistry. Fibronectin to coat coverslips and Mowiol to mount coverslips 
(Sigma-Aldrich), Vybrant Cell-Labeling solutions DiI and DiO (Molecular 
Probes/Invitrogen) were used as per manufacturer’s instructions. D-Luciferin (Gold 
Biotech #Luck) was injected for bioluminsescence detection. Prolong Gold antifade 
reagent with DAPI (Invitrogen/Gibco Life Technologies #P-36931) was used for 





 Ewing sarcoma cell lines A673 and EWS502 were grown in DMEM media with 
10%FBS, and RPMI media with 15% FBS, respectively, as previously published (Owen 
and Lessnick, 2006). Selection antibiotics puromycin (Sigma), neomycin (Gibco), 
hygromycin (Invitrogen) were used at (puromycin 2µg/ml, neomycin 300µg/ml, 
hygromycin 100µg/ml). 
Constructs and retroviruses 
Knockdown experiments used the luciferase-RNAi (as control RNAi), and EF-2-
RNAi (as EWS/FLI RNAi) constructs in pSRP retroviral vector with a puromycin 
resistance marker previously described (Chaturvedi A et al., 2012; Smith et al., 2006). 
For expression constructs, the human zyxin cDNA was cloned into pMSCV-neomycin 
retroviral vector (Clontech). The α5 integrin cDNA cloned in pMSCV-puromycin 
retroviral vector was a kind donation from Dr. Christopher Stipp (University of Iowa). 
For luciferase expression in mice, pMMP-LucNeo or pMMP-LucHygro retroviruses were 
used as previously described (Owen and Lessnick, 2006). Following retroviral infection 
for 2 days, cells were selected (puromycin, neomycin, or hygromycin) for 2 days prior to 
use and maintained for up to 5 weeks.  
Western blots 
Whole cell lysates in RIPA buffer (10 mM Tris-HCl pH7, 100 mM NaCl, 1 mM 
ETA, 1% TritonX-100, 0.5% Na-Deoxycholate, 0.1% SDS) with Complete Mini-EDTA 
free protease inhibitor cocktail tablets (Roche Diagnostics GmbH, Cat#11836153001) 
were electrophoresed (15-30 µg/lane) on 10% SDS-PAGE gels and  transferred onto 




zyxin (1:10,000), α5 integrin (1:5,000), tubulin (1:10,000) and HRP-conjugated 
secondary antibodies followed by Enhanced ChemiLuminescence detection (GE 
Healthcare). 
Immunofluorescence microscopy 
The staining, microscopy, imaging and analysis of fluorescently labeled cells was 
done as previously described (Chaturvedi A et al., 2012). A673 cells (75,000 cells) were 
plated on fibronectin-coated (10 µg/ml) coverslips in 12 well plates for 24 hrs, fixed in 
3.7% formaldehyde for 15 min. and permeabilized in 0.2% Triton X-100/PBS for 5 min. 
Cells were incubated with paxillin antibody (1:100) for 1 h at 37oC, washed (PBS), 
stained with AlexaFluor antimouse antibody (1:200), AlexaFluor phalloidin (1:100) and 
DAPI (1:600) for 1 h at 37oC, washed (PBS) and mounted in Mowiol medium.  Cells 
images were captured with a Zeiss Axioskop2 mot plus microscope with a 40X objective 
(NA 0.75 NeoFluor), Axiocam MR camera, and Axiovision v4.8.1 software (Carl Zeiss 
MicroImaging, Inc.) or with a Nikon A1R Ti inverted microscope, 60X oil objective 
(NA1.4 Plan Apo DIC N2) and Nikon Elements v3 software) . 
Cell area, number and size of focal adhesions 
To quantify these cellular features, Ewing sarcoma cells stained with paxillin 
antibody and phalloidin were analyzed using immunofluorescent images (Nikon A1R Ti 
inverted microscope with 60X Oil objective) as previously described (Chaturvedi et.al, 
2012). Briefly, using the trace tool the boundaries of phalloidin-stained cells were 
outlined and area of the selected region measured (Metamorph v7.5 software). To count 
and measure the size of the paxillin-rich focal adhesions, single-cell images were first 




freeware Image J. Image threshold was set in single cell images and the area of the 
thresholded region represented the size of focal adhesions (Metamorph imaging v 7.5 
software). At least 35 cells were analyzed for each cell type. 
Cell growth assays 
3T5 Cell growth assays were performed as described in (Smith et al., 2006). 
Briefly, 5x105 cells were seeded into 10 cm dishes for growth in tissue culture and 
counted every third day to determine the rate of cell proliferation and population 
doubling time calculated.  
Soft agar transformation assays 
These assays were performed in triplicates as previously described (Chaturvedi A 
et al., 2012; Lessnick et al., 2002). In short, 1x105 cells were seeded in 0.35% agarose 
made in Iscove’s modification Eagle’s media, penicillin/streptomycin and glutamine with 
or without selection, grown for 3-4 weeks, imaged and colony count noted. 
Adhesion assays 
Adhesion assays were performed in triplicates for each cell type following 
previously published protocols (Chaturvedi A et al., 2012; Hoffman et al.,2006).  Ewing 
sarcoma cells (300,000) were seeded in triplicate onto a non-ECM coated 24 well plate 
for 2 hrs at 37oC, fixed in 3.7% formaldehyde (15 min), stained with 1% Toluidene Blue 
for 1 h, washed, air dried and dissolved in 2% SDS. O.D. is measured at 620nm.  
In vivo mouse model 
  All animal protocols were approved by the Institutional Animal Care and Use 




River Labs strain code #394) were obtained and housed at Utah for 1 week prior to 
experiments. The intratibial model studies were modified from a previously published 
method (Guan et al., 2008).  Mouse tibias were predrilled with a 26g needle, x-rayed to 
validate needle placement, then Luciferase expressing Ewing sarcoma cells (2.5x105 cells 
in 10µl Matrigel; control A673 cells with empty vectors, A673 cells engineered to 
express zyxin, or α5 integrin or both zyxin and α5 integrin together) were injected with a 
glass Hamilton syringe and 45obevel 26g needle.  Tumor growth was monitored weekly 
for 4 weeks by injecting mice intraperitoneally with Luciferin, anesthetizing (Isoflurane) 
the mice and measuring the emitted photons/sec (Xenogen IVIS 100 Imager and Living 
Image v2.50.2 software). Tumor volume was measured with calipers and calculated using 
the formula 0.5x a x b x c, where a, b and c are the three maximum diameters.  Weekly 
X-rays were recorded (Kodak DXS4000) and osteolytic destruction of injected tibias 
were scored in a blind study by an independent analyst (L.R.). Bone lysis was graded on 
a scale of 0 to 4 where grade 0 represented no bone loss, grade 1 minimal but visible, 
grade 2 moderate (no cortex affected), grade 3 severe (cortex disrupted) and grade 4 
signifies massive bone destruction (Guan et al., 2008). After 4 weeks the mice received a 
final luciferin injection, were sacrificed, the lungs were perfused intratracheally with 4% 
paraformaldehyde, the bone tumors and lungs were removed, imaged for ex vivo 
luciferase signal and fixed in neutral buffered formalin. Ex vivo luciferase signal of 
organs (lung, liver, spleen, kidney, heart, testes, injected tibias and uninjected bones) was 
used to evaluate other sites of metastasis. Prior to paraffin embedding, the fixed lungs 





The fixed bone tumors were decalcified for 7 days before embedding in paraffin. 
The embedded tibias and lungs were sectioned and stained with H&E, or IHC with CD99 
(ARUP Laboratories, Salt Lake City UT). The expression of CD99 was detected using 
clone O-13 antimouse antibody (1:200 dilution) for 2 hrs at 37oC. Biotinylated secondary 
antibody (1:100) was applied for 32 min at 37oC. Signals were detected with a 
Streptavidin-HRP system, utilizing DAB (3-3' diaminobenzidine) as the 
chromogen (Research DAB detection kit; Ventana Medical Systems). The slides were 
counterstained with hematoxylin (Ventana Medical Systems) for 8 min, gently washed in 
dH2O/DAWN mixture, placed in iodine for 30 seconds, then dipped in sodium 
thiosulfate, dehydrated in graded alcohols (70%, 95% x2 and 100% x2), cleared in 
xylene, and then coverslips mounted (Sheryl Tripp at ARUP and YCL at HCI). The tibia 
and lung sections were evaluated by an independent clinical pathologist (A.G.) in a blind 
study.  
In vivo lung adhesion assay 
These assays were performed as previously described (Chaturvedi et al. 2012; 
Padua et al., 2008). Briefly, A673 cells with empty vector were labeled with Vybrant DiI 
(red) and A673 cells with expression of zyxin, or α5 integrin, or with both zyxin and α5 
integrin were labeled with Vybrant DiO (green). The red and green cells were mixed in a 
1:1 ratio and 1 million cells were injected into the tail-vein of NOD/SCID mice (Jackson 
Labs #1303) and allowed 24 hrs to circulate in the mouse. Mice were sacrificed after 24 
hrs, lungs were perfused intratracheally with 4% paraformaldehyde, removed and 




and examined on a Nikon A1R laser scanning confocal microscrope (9 2 µm optical 
sections, PlanFluor 40X oil DIC H N2 objective). A 3 field by 3 field (2mm X 2mm) 
mosaic image was created (NIS Elements v3 software) and red versus green colonies 
counted in 15 representative fields from 3 mice. Two such biological replicates were 
done.  
Microarray analysis 
Previously published microarray data set was reanalyzed for downregulated 
targets of EWS/FLI (Owen et al., 2008). Expression data was filtered for a 1.8-fold 
change across samples and significant changes were identified using permutation testing 
with a p-value of 0.01 after Benjamini and Hochberg correction and significant z-score in 
GeneSifter analysis software.  
Statistical analysis 
Graphs were made in and analyzed using Prism 5 software (Graph Pad, San 
Diego).  
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Figure 5.1: EWS/FLI-dependent changes in the actin cytoskeleton and contributions 
of cytoskeletal regulators. (A) Widefield fluorescent images of A673 Ewing sarcoma 
cells stained with phalloidin to visualize the actin filament network. A673 cells with 
EWS/FLI RNAi had robust actin cytoskeletons and were more spread than A673 cells 
with control RNAi. Scale bar 20 µm. (B) Western immunoblot of parent Ewing sarcoma 
A673 cells (lane 1), A673 cells with control RNAi (lane 2) or EWS/FLI RNAi (lane 3) 
were probed with antibodies for FLI-1, zyxin, α5 integrin and tubulin (loading control). 
EWS/FLI knockdown resulted in increased zyxin and α5 integrin protein.  (C) Western 
immunoblot of Ewing sarcoma cells engineered to express empty vector, zyxin, α5 
integrin, or both α5 integrin + zyxin were probed with antibodies for FLI-1, zyxin, α5 
integrin, and tubulin (loading control). Expression of zyxin or α5 integrin above the 
endogenous levels in A673 cells did not affect the level of the other protein. (D-G) 
Widefield fluorescent images of phalloidin-stained A673 cells engineered to express 
empty vector (D), zyxin (E), α5 integrin (F) or both α5 integrin + zyxin (G) suggest 










Figure 5.2:  Zyxin and α5 integrin contribute to the actin cytoskeleton, focal 
adhesions, cell spreading and cell adhesion in Ewing sarcoma cells. (A-H) A673 cells 
engineered to express empty vector (A, E), zyxin (B, F), α5 integrin (C, G) or both α5 
integrin + zyxin (D, H) were stained for actin filaments (phalloidin, A-D) and focal 
adhesions (paxillin, E-H) followed by immunofluorescent microscopy. Control A673 
cells were small and round with minimal actin stress fibers and few focal adhesions. Cells 
that express zyxin, α5 integrin, or both α5 integrin + zyxin were well spread with 
prominent focal adhesions. Focal adhesion size (I) and number per cell (J) were 
quantitated and compared between control and EWS/FLI RNAi cells and cells that 
express zyxin, α5 integrin, or both α5 integrin + zyxin. EWS/FLI knockdown and 
expression of zyxin and α5 integrin increased the size of focal adhesions. (K) Total cell 
area was measured in phalloidin-stained cells with either RNAi (control and EWS/FLI) or 
that express zyxin, α5 integrin, or both α5 integrin + zyxin. Cell spreading and size 
increased with EWS/FLI knockdown and with expression of zyxin and α5 integrin. (L) 
Cell adhesion was evaluated by plating cells for 2 hrs, followed by colorimetric detection. 
Cells with control RNAi or empty vector adhered less than cells with EWS/FLI RNAi or 
cells that express zyxin, α5 integrin, or both α5 integrin + zyxin. (M) Model of Ewing 
sarcoma cell phenotypes. The actin cytoskeleton and focal adhesions, cell spreading and 
cell area are changed by these proteins in unique and distinct ways. EWS/FLI expression 
compromises Ewing sarcoma cell adhesion by influencing the actin cytoskeleton, cell 
morphology and spreading, perhaps due to the downregulation of cell adhesion proteins 
in general and of zyxin and α5 integrin in particular. ***p < 0.001, other comparisons 





































































Figure 5.3:  Intratibial orthotopic mouse model for Ewing sarcoma recapitulates 
features of the human disease. (A) Schematic diagram of the orthotopic mouse model 
wherein A673 Ewing sarcoma cells engineered to express luciferase were injected into 
the tibia, then monitored weekly for 4 weeks for tumor growth and metastasis, followed 
by ex vivo analysis and histopathology. (B) Tibial tumor growth and proliferation of 
Ewing sarcoma cells was measured by in vivo luciferase bioluminescent imaging. (C) 
Osteolysis (white arrows indicating regions of bone loss) increased compared to the same 
mouse tibia at week 1. (D) Qualitative analysis of mouse radiographs by an independent 
analyst revealed ~85% of mice had high grade osteolysis (Grades 3 or 4) in the injected 
tibias. (E) Histopathological analysis of tibial tumors showed highly invasive tumor in 
the tibia (5X Panel 1) and closer examination (20X-panel 2, 400X-panel 3) revealed the 
presence of typical small round blue Ewing sarcoma cells.  Membranous staining for 
Ewing sarcoma marker CD99 (brown staining in panel 4) confirmed Ewing sarcoma cells 
in the tibial tumor.  (F) Mouse lung with metastatic lesions sectioned and stained by H&E 
(panel 1, 2) also contained small round blue cells typical of Ewing sarcoma and the lung 
was positive for Ewing sarcoma marker CD99 (brown staining in panel 3). (G) 

















Figure 5.4:  Zyxin and α5 integrin coexpression in Ewing sarcoma cells reduce 
tumor growth while osteolytic degradation of bone persists. (A) In vivo luciferase 
imaging 4 weeks after mice were injected intratibially with Ewing sarcoma A673 cells 
engineered to express empty vector, zyxin, α5 integrin, or both α5 integrin + zyxin. Every 
cell type was capable of inducing tibial tumors. (B) Radiographs of tibias 4 weeks 
following injections with cells that express empty vector, zyxin, α5 integrin, or both α5 
integrin + zyxin revealed high grade osteolysis (white arrows) regardless of which cell 
type was injected. (C) In vivo luciferase imaging of tibial tumors for 4 weeks. 
Bioluminescent signals restricted to the tibial tumor region were quantitated 
(photons/sec) and graphed over time. Expression of α5 integrin + zyxin in Ewing 
sarcoma slowed the tumor growth compared to the other groups. (D) 3T5 cell growth 
assay of A673 Ewing sarcoma cells with empty vector, zyxin, α5 integrin or both α5 
integrin + zyxin did not detect a difference in growth and proliferation in culture. (E) Soft 
agar transformation and colony formation of cells with empty vector, zyxin, or α5 
integrin alone were not different. However, colony formation in soft agar was inhibited in 













Figure 5.5: Ewing sarcoma cells that express zyxin and α5 integrin metastasize to 
lungs and bones. (A) Metastasis-free survival curve of mice evaluated by in vivo 
luciferase imaging of the four cell-type groups at weekly intervals. Metastasis was 
defined as appearance of bioluminescent signal other than at injection site, primarily the 
chest area. The mice injected with Ewing sarcoma A673 cells that expressed α5 integrin, 
alone or with zyxin, developed chest signal as early as week 2 or 3, while mice injected 
with control or zyxin-expressing cells developed chest signal at week 3 or 4 or not at all. 
(B) Week 4 endpoint images of in vivo luciferase signal were examined for metastasis. 
Almost all mice injected with Ewing sarcoma cells that expressed α5 integrin, either 
alone or in combination with zyxin, had significant metastasis by in vivo imaging, while 
only half the mice injected with empty vector control cells or with zyxin-expressing cells 
had in vivo chest signal at 4 weeks. Dissection of the mice revealed the chest signals were 
due to heavy involvement of lungs. (C) Lungs exhibited macroscopically visible lesions 
(column 1) that were obvious in every mouse. Paraffin-embedded lungs were sectioned, 
and H&E staining identified multiple metastases characterized by the presence of small 
round blue cells (columns 2,3). Immunohistochemistry for the Ewing sarcoma marker 
CD99 on lung sections (column 4, brown signal) confirmed the presence of Ewing 
sarcoma cells. (D) Immediately following dissection, ex vivo luciferase signals of 
multiple organs and skeletal regions were examined for each mouse. The number of mice 
displaying positive luciferase signal in bones, lungs, or other organs were scored and 
results are presented as % mice in each group.  For all groups of mice, the preferred 





















































Figure 5.6: Ewing sarcoma cells that express zyxin and α5 integrin exhibit increased 
adhesion to lung parenchyma. In vivo lung adhesion assay of Ewing sarcoma cells that 
express empty vector (colored red DiI) and cells that express zyxin, α5 integrin, or both 
α5 integrin + zyxin (labeled green DiO). Red and green cells were combined 1:1, 1 
million cells were injected into the tail vein and given 24 hrs to circulate in the mouse. At 
24 hrs, lungs were harvested, fixed, and cryosectioned. The numbers of red cell colonies 
and green cell colonies were evaluated by confocal microscopy of lung sections. (A-C) 
Maximum intensity projection of representative confocal images of lung sections, 
showing red cell colonies (empty vector, yellow arrowheads) versus green cell colonies 
(expressing zyxin and/or α5 integrin, white block arrows) for all groups of mice. Nuclei 
are stained blue using DAPI. (D) Cell colonies were counted for 15 representative 
sections 4 mm2 in area. Cells expressing zyxin or α5 integrin accumulated more in the 
lung parenchyma compared to empty vector control cells. Also, cells expressing both 









Table 5.1: Categories of downregulated target genes of EWS/FLI oncoprotein. The 
KEGG pathway groups of genes that are downregulated at least 1.8 fold by EWS/FLI are 
shown.  The top three categories modulated by EWS/FLI are genes encoding focal 
adhesion-related proteins, ECM and receptor interaction proteins, and regulators of the 
actin cytoskeleton. The KEGG analysis therefore suggests the importance of cell 













































Supplemental Figure S.1: Mouse tibial tumors of Ewing sarcoma cells engineered to 
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SUMMARY AND PERSPECTIVES 
Presence of metastatic disease is the most concerning aspect of cancer 
management and treatment. Most cancer-associated deaths are due to emergence of 
metastatic lesions in sites away from the primary tumor. Several factors, intrinsic or 
extrinsic to the tumor, could govern and contribute to the dissemination and colonization 
of tumor cells (Hanahan and Weinberg, 2011). The focus of my dissertation work has 
been to investigate the role of cytoskeletal features and, cell-substratum adhesions in 
determining tumor progression and metastasis of cancer cells. For this study I used a 
particularly metastatic pediatric tumor called Ewing sarcoma, which is a paradigm to 
investigate and understand sarcoma biology.  
Ewing sarcoma is the second most common primary bone tumor in children and 
adolescents with ~25% of all patients presenting with metastasis at diagnosis (Gurney et 
al., 1999; Spraker et al., 2012). Persistent expression of EWS/FLI is necessary for 
maintenance of the transformed phenotype in Ewing sarcoma (Prieur et al., 2004). This 
fusion protein operates as an aberrant transcription factor that dysregulates the expression 
of a large number of target genes, many of which are crucial for malignant 
transformation, and several others whose relevance in Ewing sarcoma biology is not yet 
fully recognized (Lessnick et al., 1995; May et al., 1993a; May et al., 1993b). Therefore 
for my dissertation, I focused on studying the role of EWS/FLI and its downregulated 
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targets in affecting tumor cell behavior and cell-substratum interactions in Ewing 
sarcoma. 
A loss-of-function approach via RNA interference was used for targeted 
knockdown of EWS/FLI in multiple patient-derived Ewing sarcoma cell lines which led 
to dramatic changes in Ewing sarcoma cell behavior. The presence of the EWS/FLI 
oncoprotein compromised the actin cytoskeleton, reduced cell adhesion and spreading 
and reduced integrin-based adhesions in a EWS/FLI-dependent manner which result in 
Ewing sarcoma cells maintaining low basal levels of cellular adhesion, migration and 
invasion in vitro (Chaturvedi et al., 2012). These results were consistent with other 
studies which described that modulation of cellular features is significant to Ewing 
sarcoma biology (Amsellem et al., 2005; Cerisano et al., 2004). In support of these 
phenotypes the transcriptional profiling data for EWS/FLI in Ewing sarcoma cells 
revealed the significant downregulation of focal adhesion proteins, extracellular matrix or 
ECM and receptor proteins, and cytoskeletal proteins (Chaturvedi et al., manuscript in 
preparation).  
This dissertation primarily focused on characterizing the roles of two such 
EWS/FLI downregulated targets: zyxin (a focal adhesion protein) and α5 integrin, which 
when dimerized with β1 subunit forms the receptor for binding fibronectin. I report in 
this work that zyxin and α5 integrin make unique and distinct contributions to Ewing 
sarcoma cell behavior both in vitro and in vivo (Chaturvedi et al., manuscript in 
preparation). Interestingly, in addition to the receptor (α5β1), its corresponding ligand 
fibronectin was also downregulated by EWS/FLI highlighting the vital role of receptor-
matrix interactions in Ewing sarcoma biology. However, experiments directed at 
understanding how changes in surrounding matrix environment drives changes in Ewing 
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sarcoma cell morphology and behavior are crucial in answering many important 
questions specific to Ewing sarcoma pathogenesis: Why do Ewing sarcoma cells have a 
predilection for long bones and bone marrow as the primary site of tumorigenesis? And 
why do Ewing sarcoma cells prefer lungs and bones for metastasis? As the next step 
towards answering these questions, a microarray based comparative analysis of the bulk 
tumor and its surrounding tissue at the primary site and secondary site will provide vital 
information pertinent to tumorigenesis, dissemination and colonization of Ewing sarcoma 
cells. 
My experimental data when taken together with what we know about Ewing 
sarcoma from the literature and the model of “parallel tumor growth and dissemination” 
that I have proposed during the course of this work could help elucidate some as yet 
unknown mechanisms in the pathogenesis of Ewing sarcoma. For example, Ewing 
sarcoma is a bone malignancy and the cells therefore have easy access to the vasculature. 
This led me to speculate that aggressive migratory or invasive features may not be very 
necessary for Ewing sarcoma cells to actively metastasize from the primary site. Instead, 
based on low adherence of Ewing sarcoma cells I have proposed a novel mechanism for 
early metastasis wherein reduced cell adhesion potentially facilitates enhanced 
dissemination of cancer cells into the surrounding vasculature. However, future in vivo 
experiments looking at the presence of circulatory tumor cells in the bloodstream even 
before the presence of a detectable tumor will be a way to test this hypothesis. The 
realization that a “passive/stochastic” mechanism may be followed by mesenchymal 
tumors in contrast to the “active” multistep processes of metastasis that epithelial cancer 
follow is a novel contribution of this dissertation to the field of cancer research. Although 
the work described in this dissertation was performed on Ewing sarcoma, it lays a 
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foundation to verify this paradigm and define molecular mechanisms that could regulate 
metastasis in similar malignancies.  
Although EWS/FLI largely inhibits cellular adhesion proteins, these tumor cells 
still need to maintain low basal levels of adhesion to be able to form tumors, and attach to 
and colonize secondary sites for successful metastatic lesions. Based on this discussion 
we can propose crucial roles for cytoskeletal proteins and receptor-matrix interactions to 
regulate early as well as late metastasis in Ewing sarcoma. An examination of these target 
genes dysregulated by EWS/FLI could point towards the molecular mechanisms required 
for these steps in tumor growth and metastasis.  
Although future experiments are required to test the various aspects of these 
models this dissertation lays the foundation for techniques that enable in vitro and in vivo 
studies for understanding Ewing sarcoma. An important accomplishment of my 
dissertation work was the development of an orthotopic mouse model to study growth 
and progression of Ewing sarcoma in bone. This model system permitted the study of 
Ewing sarcoma in its most relevant tissue microenvironment (a long bone or tibia of 
NOD/SCID mice) that truly represented the cell-substratum interactions we intended to 
study.  This mouse model for the first time shows Ewing sarcoma cell metastasis from a 
long bone to other boney sites such as bone of the upper limb, spine and ribs in addition 
to lungs (Chaturvedi et al., manuscript in preparation). As part of this study, a new 
method was developed in collaboration with Kendall Cooper to detect the presence of 
Ewing sarcoma cells in the blood circulation of mice using human Alu primers 
(unpublished results). The presence of circulating tumor cells indicated that, similar to 
human disease, tumor cells metastasized hematogenously. Therefore these tumors in mice 
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recapitulated characteristic features of the human disease and validate this orthotopic 
mouse model as a relevant system to study human Ewing sarcoma. 
Until now, most research in Ewing sarcoma was performed in sites other than the 
bones. Through my research I have shown the metastasis of Ewing sarcoma tumor cells 
from long bones to other bones and lungs. Collaborative studies are currently underway 
to test the roles of genes involved in regulating the osteolytic behavior of Ewing sarcoma 
using this model system. Extensive osteolysis is observed in Ewing sarcoma patients and 
was also seen in our tibial mouse model. Future studies identifying the pathways critical 
to osteolysis are necessary as most patients have significant osteolysis at presentation 
(Spraker et al., 2012). This model can be used to test drug targets that reduce or prevent 
osteolysis in patients, thereby improving disease management and may lead to more 
effective targeted therapies for patients with this devastating disease. 
After establishing the Ewing sarcoma intratibial mouse model, I used it to assess 
the contributions of EWS/FLI mediated downregulation of zyxin and/or α5 integrin in 
affecting tumor growth and metastasis. My results suggested that to promote tumor 
growth EWS/FLI upregulates some genes like NKX2.2 or NR0B1 (Kinsey et al., 2006; 
Smith et al., 2006) and also downregulates other genes such as zyxin and α5 integrin 
(Chaturvedi et al., manuscript in preparation). Interestingly, reexpression of α5 integrin 
either alone or along with zyxin in Ewing sarcoma cells increased the incidence of 
metastasis and the lesions appeared sooner in mouse lungs as well. This observation led 
me to propose another interesting aspect of Ewing sarcoma biology that the same 
oncogenic event (EWS/FLI) that downregulates genes to promote tumorigenesis could 
also compromise metastasis. Therefore, using my research I have proposed a mechanism 
by which EWS/FLI potentially uncouples tumorigenesis and metastasis, a theory that has 
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been speculated by some researchers in the field of tumor progression for years (Bernards 
and Weinberg, 2002).  Alternatively, it could be deduced that not all gene expression 
changes caused by EWS/FLI are intentional or beneficial. This theory impresses an idea 
that EWS/FLI fusion gene has not yet fully evolved as an oncogene.  
The cell biology techniques and the intratibial mouse model that have been 
developed as part of this dissertation have already been proven useful in several 
collaborative studies. In one such collaboration, the role of another cytoskeletal protein, 
the intermediate filament protein called keratin 17 (KRT17) was shown to be crucial for 
oncogenic transformation (Sankar et al., submitted for review). In another collaboration 
that employed these techniques in addition to other methods, we were able to suggest 
how Ewing sarcoma cells could maintain a balance between their epithelial-like and 
mesenchymal-like features (Wiles et al., submitted for review). This study reinforced the 
idea that Ewing sarcoma cells are largely undifferentiated cells. When taken together 
with the observations in this dissertation, it can be said that this undifferentiated nature of 
Ewing sarcoma cells facilitates their growth at primary and secondary sites and also 
explains the highly micrometastatic nature of Ewing sarcoma cells. 
Furthermore, I describe that upon knockdown of EWS/FLI, the cells exhibited 
what we called a tumor-to-mesenchymal transition (TuMT), not only phenotypically 
(such as increased cell adhesion and spreading, robust actin filaments) but also in their 
transcriptional program (Chaturvedi et al., 2012). The loss of the characteristic round cell 
morphology in Ewing sarcoma cells in the absence of EWS/FLI suggests that 
morphological features are attributable to the presence of EWS/FLI oncogene. The 
appearance of more mesenchymal features upon EWS/FLI knockdown suggested that the 
Ewing sarcoma cells were probably being “normalized” to their original phenotype. 
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These findings add to the growing body of evidence and are consistent with the current 
school of thought that progenitor cells or mesenchymal stem cells are the most likely cell 
of origin for Ewing sarcoma (Riggi et al., 2008; Tirode et al., 2007).  
My dissertation work is based on an important assumption that EWS/FLI 
expression is stable and does not change over the course of tumor growth, progression 
and metastasis. But at least in a couple of published reports it has been reported that the 
expression levels of EWS/FLI transcript changes in response to the constantly changing 
tumor microenvironment (Aryee et al., 2010; Girnita et al., 2000). Therefore, an 
alternative model needs to be considered and tested where the levels of EWS/FLI change 
in response to hypoxia, or tissue microenvironment or changes in matrix composition. It 
can then be implied that corresponding changes in the transcripts of several downstream 
targets of EWS/FLI will follow further influencing the behavior of Ewing sarcoma cells. 
Although this alternative “variable EWS/FLI expression” model needs to be tested, it 
could potentially account for deficits in the “stable EWS/FLI expression” model.  
This “variable EWS/FLI expression” model could explain the increased rates of 
metastasis at both early and later stages of disease progression. For example, it is possible 
that upon early dissemination of the less adherent tumor cells, the cells enter circulation, 
where the changing composition of serum and growth factors could transiently affect 
EWS/FLI expression, thereby changing its transcriptional signature to increase 
expression of these adhesion proteins.  EWS/FLI expression has been shown to be 
sensitive to changes in the tumor microenvironment, such as the presence of growth 
factors (Girnita et al., 2000). Another scenario which could result in modulating the 
expression of EWS/FLI is that of hypoxia, which is observed in a growing Ewing 
sarcoma tumor and has also been reported to change the transcriptional signature of 
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EWS/FLI, such as the expression of several integrins including α5 integrin (Knowles et 
al., 2010).   
In conclusion, my PhD dissertation work has identified a novel role for the 
repressed targets of EWS/FLI in Ewing sarcoma tumor progression and metastasis. 
Future work will be required to identify which proteins and cell-ECM interactions are 
critical for oncogenesis and metastasis, and how these tumor cells disseminate and 
generate metastases.  In this study I have defined the need for coordinating both 
oncogenic transformation and cellular adhesion in Ewing sarcoma. This work impresses 
the need to study the change in tumor cell behaviors in the context of its relevant micro-
environment to understand mechanisms that affect disease progression. It needs to be 
determined if these mechanisms are specific to Ewing sarcoma or widely applicable to all 
bone tumors or to sarcomas or other tumors of uncertain origin in general. In addition, 
our findings highlight the complexity of oncogenic programs and remind us that not all 
gene expression changes observed in tumors are advantageous for all aspects of tumor 
initiation and progression. 
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